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ABSTRACT 
Infection after trauma complicates the patients clinical course. Infection leads to longer 
critical care and hospital stays, has been associated with increased mortality rates and 
places considerable cost pressures on health economies. The predictors of infection 
after severe injury are not known, and the effects on outcomes other than mortality are 
under-reported.   
The overall objective of this research was to characterise factors predictive of infection 
in severely injured patients admitted to critical care. A prospective cohort study of 271 
patients investigated admission factors predictive of the development of infection. A 
second study of 280 patients evaluated post-injury immune cell changes and the 
association with infection. Thirdly the relationship between early coagulopathy and 
infections was investigated in 158 patients. Finally a study of 385 patients examined the 
use of Tranexamic Acid (TXA) and its association with infection and other outcomes.  
Infection was a significant burden for severely injured patients. Admission 
hypoperfusion was the only early characteristic associated with the development of 
infection, and a dose dependent relationship was observed between severity of shock 
and increased percentage of infection (p<0.01).  Lymphopenia prolonged to day four 
post injury was strongly predictive infection (OR 0.10, CI 0.02-0.48, p<0.01). At 24 hours, 
the anticoagulant Protein C was lower in those with infection (Infection: 70.2 iu/dL vs. 
No infection: 83.3 iu/dL p=0.02), and increased fibrinolysis was also associated with 
infectious complications (Infection: 6156 µg/L vs. No infection: 3324 µg/L p=0.03). There 
was a trend to a beneficial relationship between TXA and infection, and it was 
independently associated with reduced organ failure (OR 0.27, CI: 0.10 – 0.73, p=0.01) 
and mortality (OR 0.16 CI 0.03 - 0.86, p=0.03).   
In severely injured patients, admission shock, prolonged lymphopenia and early 
coagulation dysfunction post severe injury were independent predictors of infection. 
Timely modulation of these responses after trauma may help to reduce the burden of 
infection.  
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CHAPTER ONE INTRODUCTION 
 
1.1 The disease of trauma 
 
1.1.1 The burden of traumatic injury 
Traumatic injury is a major contributor to the global burden of disease (1).  In many 
countries, trauma is the leading cause of mortality in individuals aged up to 45 years (2), 
and in England and Wales 14,000 people die annually as a result of injury (3). Trauma is 
also the cause of significant morbidity, and many patients who survive their injuries may 
suffer in-hospital adverse events such as infection and organ failure (4, 5). Despite 
improvements in injury prevention and clinical management, trauma is still responsible 
for over 80 million lost disability-adjusted life years (DALYs).  This is higher than 
ischaemic heart disease, diarrhoeal disorders and HIV infection (6).  Longer term 
physical, psychological and social impairments following trauma are well recognised (7), 
and injury is the leading cause of disability in adults of working age (8, 9).  
 
The management of trauma also represents a serious financial burden to the health 
economy.  In Britain, it is estimated that the average in-hospital cost of a severely 
injured patient is £9,530 (10, 11). However, this figure does not include the costs of 
rehabilitation and continuing care following discharge.  The National Audit Office (NAO) 
estimates health expenditure for complex trauma management to be around £0.3-0.4 
billion annually, and suggests that the burden of severe injury on economic output 
could be up to £3.7 billion (12). 
 
1.1.2 Epidemiology of traumatic injury  
Traumatic injury causes 10% of deaths globally and is the leading cause of mortality 
from the ages of 5 to 44 years in developed countries (13, 14). The majority of trauma 
related deaths occur early in the patient’s course, either in the pre-hospital phase or in 
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the acute in-hospital period (15-17).  Injury to the central nervous system and 
uncontrollable haemorrhage are the leading causes of early death (18-21).  Subsequent 
in-hospital morbidity and mortality is predominantly attributed to the development of 
multiple organ failure (22, 23) and overwhelming infection or sepsis (5, 24).  The risk of 
death in trauma patients remain higher than matched non-injured individuals for up to 
ten years post injury   (25).  
 
Traumatic injury can be caused by blunt or penetrating force, or a combination of the 
two. Blunt injuries include falls, road traffic collisions and crush injuries whilst 
penetrating trauma involves gunshot injuries, stabbing or impalement. Blasts result in 
both blunt and penetrating injuries (26, 27), as may intentional trauma due to assault or 
deliberate self-harm (28).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 A summary of trauma in England and Wales from 2002 to 2011.  ‘Blow’ includes blunt 
assaults, ‘other’ relates to injuries sustained following industrial and agricultural incidents.  (Figure 
courtesy of the Trauma Audit & Research Network). 
 
Internationally, the predominant cause of injury in civilian populations is blunt trauma 
(16-18). This is true for the United Kingdom (UK), where the most common mechanism 
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of injury is falls (3) (Figure 1.1).  
 
1.1.3 Measuring injury severity 
The severity of injury is defined using the injury severity score (ISS) (29). This score is 
calculated retrospectively once all injuries have been diagnosed. ISS is an anatomical 
scoring system which divides the body into six regions, each assigned an abbreviated 
injury score (AIS) from 0 to 6. The three highest AIS scores are squared and added 
together to produce the ISS. An ISS ≤5 indicates minimal injury; an ISS ≥15 suggests 
severe injury whilst an ISS ≥25 signifies critical injury (29).  On the whole, increased ISS is 
associated with poorer outcome, both in terms of mortality and morbidity (30, 31). 
However, the physiological response after trauma is complex and may also influence 
outcome (32). Therefore the main limitation of the ISS is that it is an anatomical scoring 
system which does not take physiological derangement into consideration. 
Nevertheless, the ISS provides an internationally recognised score used to consistently 
convey severity of injury.   
 
1.1.4 Trauma systems and processes of care 
There is a large body of evidence which has demonstrated that organisation of regional 
trauma systems is strongly associated with better patient outcomes (33-35).  Trauma 
systems are also of benefit to society by virtue of the gain in costs per life saved (36). In 
the UK, numerous reports published over the past 25 years have identified widespread 
deficiencies in the provision of trauma care (37-40). Following the publication of the 
Healthcare for London: A Framework for Action (41) in 2007, the UK National 
Confidential Enquiry into Patient Outcome and Death (NCEPOD) published ‘Trauma: 
Who Cares?’.  This revealed inadequacies in the quality and processes of care for 60% of 
severely injured patients. (42).  This population-wide analysis of trauma care highlighted 
an imperative for organised trauma networks in the UK.  Accordingly, in April 2010 
Greater London introduced a pan-regional inclusive trauma system.  
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An inclusive system is designed to care for all injured patients in a specified 
geographical location, with collaboration between pre hospital care, hospital services, 
community facilities and local government (43).  Resources are organised to deliver 
optimal care at the most appropriate facility at the right time (44, 45). Using a hub and 
spoke model, institutions designated as Major Trauma Centres (MTCs) are specialty 
hospitals with a full complement of clinical disciplines available on site, responsible for 
treating the most severely injured patients (46). Smaller trauma units, supported by the 
MTC, will care for less injured patients within the system.  
 
Leadership provided by senior clinicians experienced in trauma management is 
associated with improvements in timing and quality of care processes (47).  Standards 
for processes such as time to diagnostic imaging or major haemorrhage management 
aim to guide early trauma resuscitation. However, the quality of evidence for processes 
of care is variable (7, 48), and the association with outcomes other than mortality or 
length of stay is poorly described (49, 50).  An important challenge for contemporary 
trauma care is to identify which early clinical processes translate into improved patient 
outcomes.  This will be best achieved through robust research studies. 
 
1.1.5 The need for trauma research 
Despite the global impact of traumatic injury, published evidence to guide management 
is limited, primarily due to a lack of research in this field. With the exception of a small 
number of established research centres in Europe and the USA, the majority of civilian 
injury research comprises data reviews from trauma registries (51).  
 
Throughout history, wars and conflict have resulted in advancements in trauma 
management (52). In 2005, a military ethical human research protection plan (HRPP) 
was drafted, facilitating research in a combat environment (53). This has enabled 
multisite, prospective research studies in combat zones such as Afghanistan and Iraq 
(54). Whilst there are differences in populations and injury mechanisms, current military 
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studies have influenced trauma research and management in civilian settings (55), in 
areas such as haemorrhage management and transfusion practices (56-59).  
 
There are however, a number of challenges for conducting civilian trauma research, and 
efforts have been hindered by the complex nature of trauma care and heterogeneous 
populations (2). There may be difficulties in enrolling patients who present 
unpredictably, in physiological extremis, and outside of traditional working hours.  
Obtaining consent in patients who may be unconscious, impaired or distressed due to 
injury adds to the challenge (60). Additionally, trauma patients may be mobile, injured 
away from home or transient within an area (51), and following up those who may not 
live close to the trauma system may be difficult after discharge.  
  
Underpinning these challenges are low levels of investment into trauma research (61).  
The RAND corporation report concluded that less than one percent of the total UK 
public expenditure on health research is allocated to trauma (62). Nevertheless, despite 
these acknowledged challenges, recent clinical trials and good quality observational 
studies have been conducted successfully (63-65). Trauma research is essential, in order 
to develop and assess new treatments, improve clinical care, and strengthen trauma 
systems (2).  
 
1.1.6 Measuring outcomes after trauma 
Outcome measurement following traumatic injury is important to many key 
stakeholders, including clinicians, healthcare systems, researchers and the public. The 
heterogeneous nature of traumatic injuries and the numerous clinical interventions 
required by this patient population means that outcome measurement is complex (6). 
Outcomes are measured in trauma research to evaluate the effect of an intervention or 
process. The challenge for current research is to identify the optimal, most sensitive 
outcome measure (or surrogate of outcome) for use in trials and clinical studies.  The 
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primary outcome measure in the majority of published trauma research is mortality. 
Whilst this is unambiguous and consequently feasible to quantify, it can be affected by 
many variables such as age, injury severity or pre-existing morbidity. Therefore, 
mortality may not be a very sensitive measure of process, intervention or the patient 
experience following injury.  
 
System based outcomes such as critical care stay, ventilator use, or length of hospital 
stay are also commonly reported. Again, there may be a number of variables, such as 
differing admission or discharge criteria, which could influence these outcomes. Other 
in-hospital or intermediate measures of outcome include development of adverse 
events such as infection, organ failure or cardiac dysfunction (66-69). These too are 
subject to variability in trauma systems, although the publication of internationally 
validated measures such as organ injury scores or infection criteria means that the 
evaluation of in-hospital outcomes is becoming increasingly more reliable.  Given that 
mortality and length of stay are affected by many non-adaptable variables, morbidity 
outcomes may provide more sensitive measures of clinical intervention and the in-
hospital patient experience (6) and as such are useful tools for evaluation of trauma 
care.  
 
 
1.2 Infection and Trauma 
1.2.1 The significance of infection in trauma patients 
Infectious complications have previously been recognised as an adverse clinical 
outcome following trauma (70-72). Infection leads to increased critical care admissions, 
longer lengths of critical care and hospital stay, and has been associated with increased 
mortality (5, 72, 73). Patients who survive infection to hospital discharge are reported 
to have decreased functional status and increased healthcare use up to a year after 
injury (74). Infections also place considerable cost pressures on health care providers 
and hospital acquired infections continue to raise safety concerns for patients (75-77) .  
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There is a lack of evidence however, on the determinants of infectious complications in 
contemporary trauma care. Studies examining the specific early characteristics that 
predispose injured patients to infection are limited. The majority of literature has 
focused on specific micro-organisms or location of infection (78-80), rather than the 
burden of trauma related infection as a whole.   
 
1.2.2 The incidence of trauma infection: the clinical evidence 
There are few clinical studies investigating the relationship between trauma and the 
overall burden of infection.  Where studies exist, more than half are derived from 
retrospective registry reviews.  Retrospective database and registry reviews can yield 
large numbers of patient data for research; however this method may fail to account for 
unmeasured variables that were not collected during initial data collection.  
 
The reported incidence of trauma related infections is variable. Historical evidence from 
large registry reviews reported a relatively low incidence of infection at 16 and 17% 
respectively (81, 82).  These studies associated infection in trauma patients with 
invasive therapeutic interventions.   Subsequent retrospective evidence reported a 
lower incidence of 9%, with trauma infections predominantly related to older age, injury 
severity and operative intervention (70). Almost a decade later, a large prospective 
study examined the risk factors associated with infection in patients admitted to a 
Canadian trauma system (71). At 37%, the incidence of infectious complications was 
much higher than the previously published evidence.  In this cohort study, infections 
most commonly affected the respiratory and urinary tracts (28% and 24% respectively). 
Multivariate regression analysis demonstrated independent relationships between 
infection and spinal injury (Odds ratio: 5.0, CI: 1.8-15.0; p<0.001), ventilation (Odds 
ratio: 2.6, CI: 1.5-4.4; p<0.01), multiple surgical interventions (Odds ratio: 2.8, CI: 1.1-
6.7; p=0.02), and multiple blood transfusions (Odds ratio: 2.9, CI: 1.8-5.0; p<0.01). 
However, patients who received an early (<24hours) operative intervention had a 
significantly lower risk of infection (Odds ratio: 0.37, CI: 0.20-0.68; p<0.001).  
Contemporary early trauma management has changed since this research was 
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conducted. Timely haemorrhage control with early operative or radiological 
intervention is now a central tenet of injury care. The reduced infection rates associated 
with early operations in this Canadian study may have reflected a protective 
relationship between timely haemorrhage management and decreased inflammatory 
responses.  
 
More recently, retrospective reviews suggested that the incidence of post-traumatic 
infection was between 6-10% (66, 83-85). Whilst this represents a relatively low burden 
of trauma-related morbidity, it may illustrate the difficulty in reporting infection data on 
patients with differing degrees of injury severity.  In patients whose injuries were severe 
enough to require intensive care admission (86), rates of infection were much higher at 
45%. Prolonged ventilation (Odds ratio: 12.8, p<0.001) and invasive devices (Odds ratio: 
4.6, p<0.001) were independently associated with the development of infection. 
However, the majority of individuals (72%) had single traumatic brain injuries, and no 
analysis of the patients’ injury severity, haemodynamic status or resuscitation 
intervention was provided.  It is difficult therefore to determine if the high incidence of 
infection reported for this cohort is representative of all multiply injured trauma 
patients. 
 
Penetrating injury is a significant cause of trauma-related morbidity, and the resulting 
open wounds may increase the incidence of infectious complications. Evidence suggests 
that both penetrating and blast injuries seen in civilian and military trauma have 
resulted in infection rates of up to 50% (84, 87, 88).  Penetrating hollow viscous injury in 
particular, is strongly associated with the development of surgical site infections (89), 
whilst infection rates in open wounds and fractures are as high as 50% in some 
orthopaedic series (90). The significant incidence of infection following penetrating 
injury has resulted in number of prophylactic management guidelines for traumatic 
wounds and open fractures (91, 92).    Conclusive high quality evidence of the efficacy of 
these recommendations is yet to be published (92-94). 
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Pneumonia continues to be the most common infection reported in trauma studies. The 
development of pneumonia in trauma patients has been associated with increased age 
(66, 83), pre-existing co-morbidities (84) and spinal cord injury (85). The burden of 
ventilator associated pneumonia (VAP) has resulted in a number of prospectively 
conducted studies. Prolonged ventilation (95), early clotting dysfunction (96), blood 
transfusion (97) and severe thoracic injury (98) have all been independently associated 
with VAP. The need for strict infection prevention and control has also been reported 
(99-101), and subsequently, critical care bundles have been introduced to minimise the 
risk of VAP (102).  Recent evaluation suggests that these interventions have led to a 
decreased incidence of this specific type of infection in trauma patients (103-105).  
 
Prospective research into the risks of VAP has provided translational evidence for 
clinical practice which has led to better outcomes for patients. However there is a 
knowledge gap in relation to the predictors of all infections in the most severely injured 
patients. Whilst some studies exist, risks have yet to be comprehensively described in 
prospective evidence. Characterisation of clinically identifiable risks may enable the 
development of prediction tools to guide the management of severely injured trauma 
patients.   
 
1.2.3 Risk factors associated with infection following trauma  
Some of the most prevalent evidence reporting risks of infection following injury has 
emanated from a group in Maryland USA.  In common with earlier studies, older age 
was found to increase the burden of trauma infection (106).  Patients over 65 years old 
had a two-fold greater infection rate than those <65 years, and this correlated with 
increased mortality and length of stay. In this cohort of patients, only COPD was found 
to be independently related to infection.   
 
In the same year, admission systemic inflammatory response syndrome (SIRS) was 
found to be an independent predictor of infection following blunt trauma (107). After 
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adjusting for age and injury severity, hypothermia and leukocytosis on admission were 
strongly associated with infection, increased length of stay and mortality.  A subsequent 
study by this group reported that persistent SIRS was also found to be highly predictive 
of infectious complications (108). Persistent SIRS was defined as a SIRS score of ≥2 daily 
from day three to seven post injury. SIRS during these time points was associated with a 
significantly increased risk of infection (SIRS present day 7 - Relative risk: 2.81, CI: 1.78-
4.48; p<0.001).  Further evaluation of this relationship was conducted, where the 
definition of persistent SIRS was extended to day 21 post injury. SIRS was still present in 
50% of patients at three weeks post injury,  and at this time point there was a  25-fold 
increased risk of infection (Odds ratio: 24.7, CI: 11.2-54.0; p<0.001) (109).  
 
Whilst these SIRS studies add to the body of knowledge about trauma-related 
infections, there are a number of limitations. SIRS is common following traumatic injury, 
and a number of variables influence its presence. None of the studies discuss the 
haemodynamic status of the patient; therefore haemorrhage, shock, use of blood 
products or other potential causes of inflammation were not included in the analysis. 
The findings do not explain if SIRS was constant during the time from injury, or whether 
the persistent SIRS was in fact a second or third episode which may have been caused 
by operative intervention or an infectious episode. Furthermore, the temporal 
relationship between the development of SIRS and diagnosis of infection was omitted 
from these studies. A final limitation of this work is that analysis of immune cells other 
than leukocytes was not conducted, which may have revealed a more about the 
inflammatory response to trauma.  
 
Evidence of the relationship between trauma haemorrhage and the development of 
infection is very limited. There are a small number of studies that report an association 
between trauma-related infection and administration of blood products.  A dose 
dependent relationship was found between red cell transfusion and post trauma 
infection (110). Adjusting for age and injury severity, multivariate regression confirmed 
an independent association between packed red cells and the development of infection 
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(Odds ratio: 1.08, CI: 1.02-1.14; p<0.01). Red cell transfusions per patient ranged from 0 
to 46 units, suggesting a degree of uncontrolled haemorrhage in some patients, 
however this factor was not included in the analysis. A similar study reported that the 
odds of infection were eightfold greater in transfused patients (Odds ratio: 7.9, CI: 2.3-
27.5; p < 0.001) compared to matched controls having received no blood, independent 
of age and ISS (111).  Patients who received blood were significantly more shocked and 
coagulopathic on arrival to hospital, yet neither of these potentially confounding 
variables were considered in the evaluation of results.  
  
Conversely, two studies suggest that it is not the volume of red cell transfusion that 
contributes to an infection risk, but the age of blood products used after trauma.  A 
small retrospective review of 61 severely injured patients (ISS>15) matched for age, 
injury severity and admission hypoperfusion reported an increased association between 
transfusion of blood greater than 14 days old and infection (Odds ratio: 1.12, CI: 1.01-
1.26, p=0.03)  (112). These findings were confirmed in a larger cohort of 196 severely 
injured patients, who suffered a 29% incidence of infection. After adjusting for ISS, 
operative interventions and antibiotic use, older blood was independently associated 
with infection (Odds ratio: 1.03, CI: 1.01-1.07; p=0.03) (113). Biochemical changes 
occurring during prolonged red cell storage (leading up to expiry) result in activation of 
the immune system (114), which may explain the increased infection risk in these 
studies.   
 
Finally, elevated body mass index (specifically BMI> 30), has been linked to increased 
infectious complications following injury (115). Obese patients had a five-fold increase 
in infections and furthermore, morbid obesity resulted in a six-fold increased risk. 
Uncontrolled glycaemic control post injury in obese and diabetic patients was also 
strongly predictive of infection (67), with a dose dependent increase in infections 
associated with rising blood glucose. Whilst these findings are important in 
understanding potential risk of infection, obesity may be a complicating factor for only a 
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limited number of trauma patients.  Other more common patient, injury or physiological 
variables may be more predictive of infection risk for the majority. 
 
Infection prevention and control processes are an important part of contemporary 
trauma management, yet the risk of infection is still considerable. Invasive interventions 
and mechanical ventilation are established factors for increased risk of infection, and 
care bundles help to mitigate this. However the evidence has yet to identify predictors 
of all types of infection in a severely injured population.  Inflammatory changes have 
been implicated in the development of infectious complications; though the published 
research is limited to evaluation of early and persistent SIRS responses. Analysis of 
other immune system changes following trauma may add to this knowledge. Evidence 
relating to haemorrhage and coagulopathy as drivers of trauma infections is 
predominantly restricted to the association with blood transfusions. The involvement of 
trauma haemorrhage and coagulopathy in the development of infection in severely 
injured civilian patients remains uninvestigated. 
 
1.2.4 Infection after trauma: the military evidence 
Combat related injuries are complicated by higher rates of infection. Blasts cause both 
blunt and penetrating forces resulting in wounds, soft tissue injury and mangled 
extremities, and are strongly associated with infection (87, 116-118).  As a result of 
recent conflicts, military trauma studies have led to a renewed focus on post-injury 
infectious complications (119). Generally, sites of combat trauma infection and specific 
microbes differ from civilian reports (118, 120), and specific contemporary conflict 
mechanisms such as blasts caused by improvised explosive devices, tend to confer a 
high risk of infection, (87, 118).  
 
Trauma care in a military setting has obvious differences to civilian trauma systems. 
Initial management may start in the field and move through increasing levels of care 
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until the patient is repatriated back to a home based hospital. The number of 
environmental, physiological and clinical challenges this presents for trauma infection 
control have resulted in the Guidelines for the Prevention of Infections Associated With 
Combat-Related Injuries (121). A current ongoing study aims to monitor adherence to 
these guidelines and evaluate outcomes in military trauma patients with infection. The 
Trauma Infectious Diseases Outcomes study (TIDOS) is a five year observational 
investigation retrospectively recruiting patients who developed infection during various 
echelons of military trauma care (119). Prospective follow up is conducted at pre-
specified time points over five years following discharge.  Initial analysis from the first 
year of study reported a 27% infection rate, with a predominance of wound infections, 
pneumonia and osteomyelitis. Findings suggested that patients who develop infection 
tended to be more extensively injured requiring prolonged hospital stays.  More 
detailed outcomes analysis is yet to be reported. This study will encompass significant 
numbers of participants yielding contemporary data to add to the body of knowledge 
on trauma infections. The challenge will be to extrapolate combat zone practice and 
infectious outcomes to the civilian trauma setting.  
 
1.2.5 Prophylactic antibiotic use after trauma 
Antibiotic prophylaxis prior to elective surgery is well established and is reported to 
significantly decrease surgical site and other post-operative infections (122, 123). Yet 
there is a paucity of level one evidence to support the practice following major trauma 
(94, 124). Historically, prophylactic antibiotic guidance for trauma patients has focussed 
on penetrating abdominal injuries (125, 126) and open fractures (127, 128). More 
recently, findings from a systematic review supported the use of prophylaxis for 
penetrating thoracic trauma (129), and this illustrates that much of the available 
evidence focuses on single system injuries (92, 130). Currently there is a lack of 
prophylaxis guidelines for patients following multiple severe trauma. Furthermore, a 
major challenge of exposing patients to antibiotics is the emergence of drug-resistant 
bacterial strains (131).  Gram negative pathogens resistant to broad spectrum 
antibiotics continue to increase (131, 132). At the same time there is a lack of new 
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antibiotics being developed, therefore the availability of treatment options is narrowing 
(133). As a result, current evidence suggests that early but time-limited antibiotic 
prophylaxis is needed to both decrease post-traumatic infections and minimise 
resistance (132, 134). 
 
There is an ongoing debate about the duration of antibiotic prophylaxis following 
trauma. Historical (125, 135) and more recent evidence (92, 124) has debated the 
appropriate timing of prophylactic antibiotics in trauma patients. This literature reports 
that prophylaxis for more than 24 hours after injury does not offer enhanced protection 
against infection, and may increase susceptibility to resistance.  A recent systematic 
review suggested that the risk of bacterial resistance caused by antibiotic administration 
for 48 hours or more after trauma outweighed potential benefits(132). This conclusion 
was based on what was described as ‘uncertain evidence’ and illustrates the lack of 
quality research trials and clinical consensus in this area of trauma management.   
 
1.2.6 Outcomes following trauma infections 
Research specifically investigating patient outcomes as a consequence of post-traumatic 
infection predominantly focuses on mortality, length of stay and cost.  Mortality rates 
for those who developed infection after injury range from 2-29%. A large retrospective 
review reported that patients with infection who subsequently developed sepsis had  
nearly a six-fold greater risk of death compared to those without (Odds Ratio: 5.7, 
p<0.001) (136).  Conversely, an earlier large database review of trauma patients found 
no difference in mortality for those with or without infection (83). However, studies 
using mortality as a primary outcome varied widely in their methods and patient 
populations and assessment of outcome rendering them difficult to compare.   
 
There are a number of variables which affect length of stay following trauma, and 
infection is reported to have an adverse effect on this outcome measure.  One study 
reported increased hospital stays for patients with infection (83). Only 2% of non-
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infected individuals were still in hospital at day 15 following injury, compared to 16% of 
those suffering infectious complications.  In research evaluating patients admitted to 
hospital following road traffic collision, the presence of spinal cord injury was strongly 
associated with the development of infection (85). Outcome evaluation in this cohort 
revealed an almost three-fold increase in average length of stay for those suffering 
infection (No infection: 13 days, vs. Infection: 33 days, p<0.001). The availability of 
specialist or rehabilitation services for spinal cord injured patient may also influence 
length of stay, however the effects of this were not included in the analysis.  
 
Only one study specifically reported the impact of in-hospital infection on post 
discharge status (74). Long term outcome analysis revealed worse physical function for 
up to a year post injury. Patients who had experienced infection reported delayed 
return to pre injury employment and increased readmission rates when compared to 
those without infection (74).  
 
Mortality and length of stay are important measures of outcome, yet the development 
of infection may also have a significant impact on the patients clinical experience in 
hospital. Published reports do not fully reflect the effect of infection on other outcomes 
such as organ failure, cardiac injury or venous thromboembolism. A strong association 
between infection and other outcomes may provide sufficient evidence for this to 
become a surrogate outcome in future trauma clinical trials.     
 
 
1.3 Physiological Responses to Trauma 
1.3.1 The immune cell response and traumatic injury 
The immune system is divided into innate and adaptive responses. The innate immune 
system is the first level of host defence against infection (137). It is an inherited, evolved 
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defence mechanism which provides an immediate, non-specific response to harmful 
stimuli (138).  The adaptive immune system is acquired during a lifetime, creating an 
immunological memory in order to respond to subsequent harmful pathogens (137). 
The adaptive response is recruited by the innate immune system to supply antibodies to 
attack specific pathogens (138).  Evidence suggests that traumatic injury precipitates a 
state of immune-suppression which puts patients at risk of pathogen invasion (139, 
140). The immune system response to trauma involves a number of different white 
blood cells (leukocytes). These include granulocytes, primarily neutrophils and 
monocytes, and agranulocytes, namely lymphocytes.  
 
1.3.1.i Neutrophils 
Neutrophils represent between 50 and 60% of all circulating leukocytes and together 
with monocytes, are the first cells rapidly mobilised in the inflammatory response to 
trauma (141, 142).  Neutrophil numbers are significantly higher in the initial phase 
following injury (143), recruited by the proinflammatory cytokine response (144). They 
contribute to a natural immunological defence against microorganisms within minutes 
of the initial insult (145), lasting up to 72 hours (142). Neutrophils have been implicated 
in the development of adverse events following trauma. Prolonged inflammation 
resulting in neutrophil sequestration has been associated with tissue damage leading to 
the development of MOF (146). Conversely, in patients who sustained a single 
penetrating injury necessitating operative intervention, early post-operative neutrophil 
counts demonstrated that neutrophil apoptosis was inversely related to the 
development of infection (147). In this specific cohort reduced circulating neutrophils 
resulted in a dampened inflammatory response, thereby limiting tissue injury and 
infection.   
 
1.3.1.ii  Monocytes 
Monocytes, together with neutrophils, are fundamental to the innate immune response 
following injury.  They have both pro and anti-inflammatory actions (148). The main 
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functions of monocytes are phagocytosis and production of cytokines. However, they 
also play a central role in antigen presentation for recruiting the adaptive immune 
response (140), namely T-lymphocytes.  Severe injury has been associated with 
alterations in monocyte function resulting in decreased cytokine production (149). 
Furthermore, monocyte dysfunction frequently co-exists with lymphocyte apoptosis 
following traumatic injury, and is associated with an increased risk of MOF, acute 
respiratory distress syndrome (ARDS) and sepsis (150).   
 
1.3.1.iii Lymphocytes 
Lymphocytes were traditionally thought to be solely part of the adaptive immune 
response, however, T-lymphocytes have been shown to also contribute to innate 
immunity (143, 151, 152). Lymphocytes play an important role in the modulation of 
inflammation after injury and thus have the potential to affect patient outcome. In the 
early phases following injury, immunosuppression characterised by lowered lymphocyte 
counts has been observed (144).  Historic evidence suggests that T cell apoptosis was 
thought to be responsible for declining lymphocyte function following trauma (153, 
154) but the exact mechanism for this was unclear. Post injury immunosuppression was 
previously attributed to an anti-inflammatory response, known as compensatory anti-
inflammatory response syndrome (CARS) (144, 155). This was thought to occur after the 
SIRS response, in order to reduce or ‘re-balance’ the inflammatory state (156, 157) . 
However, recent genomic studies have questioned this temporal relationship, and 
suggest both processes occur simultaneously at an early time point following severe 
injury (152, 158, 159).  
 
The exact mechanism of how lymphocyte counts may be lowered following trauma and 
the effects of this on outcome are not well described. Anti-inflammatory processes are 
required to limit the inflammatory response to severe injury, yet a protracted period of 
immune suppression has been reported to be harmful.  Historic evidence suggested 
decreases in lymphocyte responsiveness lasting up to three days from admission 
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predisposed critically unwell patients to sepsis (160).   In a small group of blunt trauma 
patients (n=17), depressed lymphocyte responses were associated with the 
development of MOF and severe sepsis (161). Early, prolonged activation of lymphocyte 
responses after trauma followed by cellular ‘exhaustion’, where counts fail to return to 
normal within three to four days post injury was strongly predictive of mortality (153, 
162).  Whether lymphocyte count changes after trauma predict the development of 
infection is unclear.  
 
1.3.2 Inflammation and trauma 
The acute inflammatory response to trauma is a complex process which starts early 
following injury (163).  The level of inflammatory response correlates with the severity 
of injury and is associated with increased mortality and morbidity (164). Inflammation is 
driven by a number of immune response pathways and inflammatory mediators which 
are activated after injury (141). Trauma results in an initial state of sterile inflammation 
which occurs without microbial contamination (165, 166). This inflammatory process is 
thought have a similar mechanism to the immune system response to bacteria, except 
the stimulus is tissue damage (167).  Following traumatic injury, endogenous ‘danger 
signals’ are released from necrotic or dying cells (168). In response, innate immune cell 
populations are mobilised from the lymph nodes, bone marrow, spleen and tissues. The 
innate immune cells recognise the so-called ‘danger –response’ alarm signals (alarmin 
molecules, also known as danger-associated molecular patterns: DAMPs) (166, 167, 
169). The interaction between alarmins, DAMPs and the immune cells activates 
proinflammatory cytokines, resulting in inflammation (167, 170). 
 
Severe injury can lead to an inflammatory response similar to that seen in sepsis (155, 
171).  An excessive release of proinflammatory mediators may result in an early, 
widespread systemic inflammatory response (SIRS) (172). The diagnosis of SIRS is made 
when at least two of the four clinical parameters seen in Table 1.1 are present. 
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Table 1.1 Clinical parameters of systemic inflammatory response syndrome (SIRS) 
Parameter Physiological change 
Temperature > 38.8C or < 36.8C 
Heart rate  > 90/min 
Respiratory rate > 20/min, or hyperventilation defined as  
PaCO2 < 32 mmHg 
Leukocytes WBC> 12,000/mm3 or < 4000/mm3 
Or, the presence of >10% immature neutrophils 
Source: Bone et al. Definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis; 2009 
 
The degree of SIRS is dependent both on endogenous factors such as metabolic 
acidosis, and exogenous factors such as the extent of tissue injury (144).  The function 
of post injury inflammation is primarily physiological, acting as a defence mechanism to 
limit damage, promote healing and prevent further harm (137, 141). Therefore, mild to 
moderate SIRS may be considered an appropriate response to trauma.  However, a 
persistent, overwhelming inflammatory response may contribute to the development of 
multiple organ failure (137, 173, 174).  Furthermore, a sustained and severe SIRS 
response may be predictive of infections (108, 109).  
 
1.3.3 Multiple organ failure after trauma 
Multiple organ dysfunction syndrome (MODS), describes organ dysfunction present in 
the first 48 hours following injury (175). Post resuscitation organ dysfunction is common 
in severe injury and usually resolves within 48 hours (69). This differs from multiple 
organ failure (MOF), which is a dysfunctional systemic inflammatory response to 
haemorrhage and subsequent reperfusion injury (23, 68).  MOF is frequently reported in 
severely injured trauma patients, although it is an adverse outcome in many other 
clinical conditions (144). Nonetheless, trauma is a heterogeneous disease and MOF as a 
result of injury varies in time course and outcome (18, 69, 175).  The diagnosis of MOF 
lacks an international gold standard (68), and a number of scoring systems have been 
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developed including the Sequential Organ Failure Assessment Score (SOFA) (176) and 
the Denver Score (23). These scores provide simple, objective methods of defining and 
describing individual and multiple organ failure.  
 
Historic studies observed a bimodal pattern of MOF development characterised by 
‘early’ and ‘delayed’ organ dysfunction (177) . Recent studies have challenged this 
pattern and it is now accepted that the onset of MOF has a multimodal distribution (23). 
Most episodes of MOF peak from 48-72 hours following injury, although MOF may 
develop at any point later in the clinical course as a response to adverse events such as 
infection or renal failure (178). Recent reports of persistent inflammation-
immunosuppression catabolism syndrome (PICS) suggest that this is a late, non-
resolving MOF, which further complicates patient recovery and prolongs critical care 
stay (158, 159, 179). PICS currently lacks a standard definition however clinical 
determinants include prolonged immunosuppression (lymphocyte count <0.8 x109/L), 
persistent inflammation (C-Reactive Protein [CRP]>150 µg/dl) and a critical care stay of 
more than ten days (158). 
 
MOF as a result of injury affects between 14 and 40% of trauma patients (22, 23, 178). It 
has been suggested that MOF-related mortality has decreased over the past decade, 
possibly as a result of contemporary trauma resuscitation practice and improved critical 
care (23). Risk factors for the development of MOF have altered since early definitions 
in 1990s, and current evidence reports that age and administration of blood products 
are independently associated with an increased risk of organ failure (22, 23). Further, a 
recent study found a strong association between admission shock and the early 
development of MOF (at 48-72 hours) in blunt injured patients (178). In this cohort 75% 
of patients who developed MOF also developed an infection. Of note, infection 
occurred seven days after the diagnosis of MOF and was therefore not temporally 
associated with organ failure.  Whilst admission shock was revealed to be a potential 
driver for the development of MOF, the relationship between hypoperfusion and 
infection was not reported.  
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In summary, immune cell behaviour and subsequent inflammation processes following 
severe injury are complex, involving a number of interconnected responses. Early 
immune cell counts, especially in lymphocytes, have been associated with mortality and 
MOF after trauma. However evidence of the relationship between immune cell counts 
and infection following severe injury is limited.  
 
1.3.4 Haemorrhage and coagulation dysfunction after trauma 
Uncontrolled haemorrhage following trauma is responsible for up to 40% of early in-
hospital deaths (18) and despite modern trauma resuscitation, remains the most 
common and preventable cause of mortality (58, 180). Traumatic haemorrhage is also 
associated with morbidity, where uncontrolled hypoperfusion, packed red cell 
transfusion and low admission platelet counts are reported to predict the development 
of organ failure (22, 23, 69). Injury related changes to the endothelial lining of the 
microcirculation occur early, and contribute to the development of trauma induced 
coagulopathy (181).  One in four severely injured patients presents to hospital with 
significant coagulation dysfunction (21, 182).  
 
Acute traumatic coagulopathy (ATC) is an early, endogenous process characterised by 
systemic anticoagulation and global fibrinolysis (183). ATC appears to be driven by 
tissue damage and hypovolaemic shock, mediated through activation of the 
anticoagulant protein C pathways (184). The state of ATC develops rapidly following 
injury and presents early in the patients course, prior to or independent of any clinical 
intervention (185, 186). Patients presenting with ATC are reported to have up to 50% 
mortality rates and a higher incidence of adverse clinical outcomes such as lung injury, 
sepsis and multiple organ failure (185). Once activated, protein C is associated with a 
reduction in clotting factors V and VIII, thus slowing down coagulation and producing 
negative effects on clot strength (187). Inhibition of fibrin formation and increased 
fibrinolysis are also a key component of ATC (188). Following injury, tissue plasminogen 
activator (tPA) is slowly released from the endothelium (189), converting plasminogen 
to plasmin, resulting in fibrinolysis. Following activation of protein C in ATC, 
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Plasminogen Activator Inhibitor-1 (PAI-1), a protein which normally inhibits tPA is 
depleted (190). This leads to a de-repression of fibrinolytic activity, resulting in global or 
‘hyper’ fibrinolysis (183, 191). In trauma patients, hyperfibrinolysis is strongly associated 
with worsening coagulation and increased mortality (188, 192).  
 
1.3.5 Management of trauma haemorrhage and coagulopathy  
Initial management of trauma haemorrhage includes administration of crystalloids, red 
blood cells, plasma, and platelets (58, 193). However, haemorrhage related dysfunction 
of the microcirculation and subsequent coagulopathy cannot be corrected by volume 
replacement alone (194). Fluid resuscitation may result in persistent coagulopathy, 
further bleeding, and poor outcomes (195). Whilst evidence for optimal management 
and therapeutic targets is lacking at the current time, early haemorrhage control 
combined with correction of coagulopathy are most likely to reduce the impact of 
coagulation dysfunction and improve outcomes for bleeding patients (196). 
Contemporary haemorrhage control techniques range from application of prehospital 
limb tourniquets (59, 197), haemostatic dressings (198) or balloon occlusion of the aorta 
(57), to early angioembolisation of bleeding vessels (196) or emergency damage control 
surgery (193, 199).  
 
Haemostatic resuscitation (HR) used in conjunction with haemorrhage control was 
developed to assist in the management of trauma induced coagulopathy (200). HR 
involves targeted blood component transfusion including platelets, plasma and 
cryoprecipitate, delivered as part of a major haemorrhage protocol (196, 201). However 
evidence to support the use of HR in the treatment of coagulopathy is limited. Higher 
plasma to platelet ratios early in resuscitation have been associated with decreased 
mortality during the first 24 hours of admission, yet after this time point plasma and 
platelet ratios showed no mortality benefits (58). Further, a recent study observed that 
correction of coagulopathy does not occur until haemorrhage control is achieved, 
regardless of blood component ratios (202). 
42 
 
ATC is also characterised by global fibrinolysis.  Recent studies have reported rates of 
admission hyperfibrinolysis to be between 25- 66% of severely injured patients (188, 
192).  Tranexamic acid (TXA) is an anti-fibrinolytic, anti-inflammatory drug which 
occupies lysine binding sites on plasminogen, thereby inhibiting plasmin and limiting 
clot breakdown (186, 191). In a single large multicentre randomized control trial (64) 
TXA, when given within three hours of injury, demonstrated survival benefits in trauma 
patients known or suspected to be bleeding. Similar mortality benefits were seen for 
combat zone patients requiring massive transfusion, where TXA also resulted in an 
improved coagulation profile (203).  These findings have led many services to include 
TXA in their major hemorrhage protocols (193, 204). Whilst the exact mechanism of 
action of TXA in bleeding trauma patients is unclear (205) its use is a safe and 
inexpensive step towards improving the management of haemorrhage and 
coagulopathy (191). TXA also has anti-inflammatory properties. Plasminogen binds to 
receptors of cells involved in the development of inflammation process, such as 
monocytes, neutrophils, and platelets (206). By blocking the binding to these receptors, 
TXA may modulate the inflammatory response and susceptibility to infection.  
 
Uncontrolled haemorrhage following trauma is a significant cause of mortality and 
morbidity.  Coagulopathy caused by bleeding and tissue damage occurs early after 
injury and challenges clinical management. Additionally, traumatic haemorrhage and 
resuscitation induces a cellular ischaemia-reperfusion injury which leads to the 
activation of an inflammatory response (187, 196). This interplay between the 
coagulation and inflammatory systems following trauma may further affect outcomes 
for severely injured patients (181), and be implicated in the development of infection. 
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Study  
 
Design 
 
Trauma 
Population 
 
Primary 
Variable 
 
Infection  
Rate 
 
Principle Site 
of Infection 
 
Time to 
infection 
 
Risk Factors for 
Infection 
 
      Outcomes 
Caplan 1981 
Retrospective 
registry review 
All trauma 
patients  
Infection 16% 
Bacteraemia 
(21%) 
N/S Invasive  devices Mortality (14%) 
Caplan 1985 
Retrospective 
registry review 
All trauma 
patients 
Infection 17% 
Vascular 
access sites 
(21%) 
N/S Invasive  devices Antibiotic use 
Pories 1991 
Retrospective 
registry review 
All trauma 
patients 
Infection 9% 
Urinary tract 
infection (61%) 
N/S 
Age, spinal and 
thoracic injury, 
surgery  
Length of stay (LOS) 
Papia 1999 
Prospective 
cohort 
All trauma 
patients 
Infection 37% 
Respiratory 
tract (28%) 
23 days 
Ventilation, surgery, 
blood transfusion 
Mortality (2%) 
Bochicchio 
2001 
Prospective 
cohort 
All trauma 
patients 
Age > 65 
years 
39% 
Respiratory 
tract (49%) 
N/S 
Chronic obstructive 
pulmonary disease 
Infection, Mortality 
(28%), LOS 
Bochicchio 
2001 
Prospective 
cohort 
Blunt injured 
patients 
SIRS on 
admission 
31% 
Respiratory 
tract (38%) 
N/S 
Admission 
hypothermia and 
leukocytosis 
 
Infection, Mortality 
(8%),  LOS 
Bochicchio 
2002 
Prospective 
cohort 
All trauma ICU 
admissions  
Persistent 
SIRS 
41% 
Respiratory 
tract (33%) 
8 days 
SIRS persisting to 
day 7 post injury 
Mortality (12%), 
Ventilator days, 
LOS 
Offner 2002 
Retrospective 
database review 
Trauma ICU 
ISS>15 
Blood 
transfusion 
40% 
Respiratory 
tract (61%) 
7 days 
Transfusion of blood 
>14 & 21 days old 
Infection 
Lazarus 2005 
Retrospective 
registry review 
All trauma 
patients 
Infection 9% 
Respiratory 
tract (42%) 
N/S 
SIRS, surgery, 
invasive devices 
Mortality (8%), LOS, 
Costs  
Hoover 2006 
Prospective 
cohort 
All trauma ICU 
admissions 
SIRS up to day 
21 
45% 
Respiratory 
tract (22%) 
8 days 
Admission and 
persistent SIRS 
Infection, Mortality 
(14%) 
Table 1.2 Summary of civilian trauma studies reporting risks and outcomes of infection 
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Lazarus 2007 
Retrospective 
registry review 
All trauma 
patients 
Infection 9% 
Respiratory 
tract (42%) 
N/S 
Age, ISS, multiple 
injuries 
Infection only 
Giamberardino 
2007 
Retrospective 
registry review 
All trauma 
patients 
Infection 45% 
Respiratory 
tract (49%) 
6 days 
Multiple injuries, 
ventilation, surgery, 
invasive devices 
Mortality (29%) 
Czaja 2009 
Retrospective 
database review 
Trauma 
patients aged 
18-84 
Infection 14% 
Respiratory 
tract (57%) 
N/S 
Male<65 years, 
obesity, ISS, blood 
transfusion 
Mortality ≤1 year, 
Functional outcome, 
Return to work,           
Re-admission 
Sadjadi 2009 
Retrospective 
study 
All trauma 
patients 
Blood 
transfusion 
51% 
Respiratory 
tract (61%) 
N/S Blood transfusion Infection 
Yun 2010 
Retrospective 
registry review 
All trauma 
patients 
Infection in 
burns and 
trauma  
8% 
Respiratory 
tract (8%) 
7 days 
Burns, age, ISS, GCS,                       
comorbidities 
Mortality (8%), ICU 
and hospital LOS 
Serrano 2010 
Retrospective 
database review 
All trauma 
patients 
Obesity 8% 
Respiratory 
tract (28%) 
N/S 
BMI, age, ISS, ICU,                       
comorbidities 
Ventilator days, 
ICU and hospital LOS 
Bochicchio 
2010 
Prospective 
cohort 
All trauma ICU 
admissions 
Blood glucose 
elevation 
28% 
Urinary tract 
(16%) 
< 14 days 
Glucose instability, 
age, ISS, obesity, 
diabetes mellitus 
Mortality (26%), 
ventilator days, 
ICU and hospital LOS 
Glance 2011 
Retrospective 
database review 
All trauma 
patients 
Infection 5% 
Respiratory 
tract (2%)  
N/S 
Mechanism of 
injury, head and 
chest injuries 
Mortality (ICD10 
coding), LOS, costs 
Fraser 2011 
Retrospective 
registry review 
Vehicular 
trauma 
Infection 6% 
Urinary tract 
(11%) 
N/S 
Age, spinal cord 
injuries 
ICU and hospital LOS, 
costs 
Juffermans 
2012 
Retrospective 
database review 
All trauma ICU 
admissions 
Blood 
transfusion 
29% 
Respiratory 
tract (46%) 
N/S 
Transfusion of blood 
>14 days old 
Infection, Mortality 
(4%),  ventilator days 
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1.4 Project objective and aims 
 
The overall research objective was to characterise factors predictive of infection in 
severely injured patients.  Specifically, the project aims were: 
 
Aim 1. To describe the burden of infections associated with severe injury. 
Aim 2. To determine the admission characteristics of severely injured patients who 
develop infection. 
Aim 3. To evaluate the relationship between early immune cell changes after injury and 
the subsequent development of infection.  
Aim 4. To establish whether there is an association between changes in the coagulation 
system following injury and the subsequent development of infection.  
Aim 5. To evaluate the early use of antifibrinolytics on the development of infection 
following injury.  
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CHAPTER TWO METHODS 
 
2.1 Study design and setting 
This research was a prospective observational study of severely injured patients 
admitted to a Major Trauma Centre between September 2010 and September 2013. 
Patients recruited into this research were enrolled into one of two ongoing 
observational studies within the Centre for Trauma Sciences: Prospective Outcome 
Evaluation following Trauma (POET) or Activation of Inflammation and Coagulation in 
Trauma (ACIT II). The POET study was devised and conducted by myself and Karen 
Hoffman (Research Occupational Therapist). The aims were to investigate infection and 
other adverse outcomes in severely injured patients admitted to critical care (Elaine 
Cole) and post discharge (Karen Hoffman). ACIT II is an ongoing study of various aspects 
of haemorrhage and coagulation dysfunction following traumatic injury (63). 
 
2.1.2 Study participants 
All adult trauma patients (>15 years) requiring trauma team activation on arrival and 
subsequently admitted to the adult critical care unit (ACCU) were enrolled. Criteria for 
trauma team activation are listed in Table 2.1.   
 
Patients were excluded from ACIT II if there had been a delayed presentation of more 
than two hours after injury, the administration of over two litres of intravenous fluid 
prior to Emergency Department (ED) arrival, transfer from another hospital, burns >5% 
total body surface area, known to be taking anticoagulant medication and those with 
known bleeding diathesis.  For both POET and ACIT II, patients were excluded if they 
declined to give consent to participate. Finally, severity of injury was calculated using 
the injury severity score (ISS), and patients with an ISS of less than 16 were excluded 
retrospectively.   
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Table 2.1 Trauma team activation criteria 
Request by the Helicopter Emergency Medical Service or the London Ambulance 
Service, or: 
History of 
Person hit by train  
Person trapped under vehicle 
Fatality in same vehicle as occupant 
Occupant ejected from vehicle 
Fall from >2 metres 
Presentation with 
Amputation proximal to wrist or ankle 
Spinal trauma with altered neurology 
Chest trauma with altered physiology 
Polytrauma with burns 
GCS <14 or Respiratory Rate <10 or >29 or Systolic BP <90 
Penetrating trauma  
Clinical suspicion of 
Open or depressed skull fracture 
Pelvic fracture 
Major haemorrhage 
 
2.2 Consent process 
POET was originally reviewed and granted ethical approval by City Road and 
Whittington Research Ethics Committee in January 2011 (11/LO/1876), and ACIT II by 
East London and the City Research Ethics Committee 1 in November 2007 
(07/Q0603/29). 
 
The majority of severely injured patients enrolled into this study arrived at hospital with 
an altered conscious level, either as a result of injury or as a consequence of intubation 
or medication.  Those patients who were conscious may have been incapacitated due to 
pain or psychological distress.  As such it may have been inappropriate to discuss 
trauma research at that time-point and ensure patient comprehension. For ACIT II a 
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hierarchy of consent was therefore used to recruit patients who were unable to give 
consent prior to the collection of the research blood samples taken in the ED. Trauma 
team leaders (ED Consultants), all of whom were independent to the study, acted as the 
patients advocate and were thus appointed as their Professional Legally Appointed 
Representative (pLAR).  If consent was granted by the pLAR, continued participation was 
sought from the patient as a priority.  Until such time as the patient had capacity, next 
of kin acted as the consultee, and were asked to consider the wishes of the patient.   
 
Patients and consultees were provided with detailed information sheets and time to 
consider involvement in POET and ACIT II.  If consent was refused or retracted by either 
the patient or consultee, then participation was withdrawn.  In ACIT II, if a patient died 
before personally giving consent, the consultee was approached for permission to 
continue the use of samples and patient data for the study.  Access to medical notes, 
pathology test results and patient follow up interviews were required for POET, 
therefore an invitation to participate in the research was given as soon as the patient 
was awake and able to comprehend the study aims and protocol.   
 
A paper record of all consent procedures and patient reviews were kept locked in a 
secure cupboard within a locked office.  Anonymised, password protected electronic 
records were stored in a secure research database within the Centre for Trauma 
Sciences. 
 
2.3 Data collection  
Admission data were collected prospectively on patient demographics, time and 
mechanism of injury, baseline physiology, coagulation and immune cell profiles.  
Admission arterial blood analysis for base deficit (BD) was performed during the trauma 
team resuscitation as part of normal care processes. BD was utilised to detect and 
predict the severity of hypovolaemic shock on admission to the ED (207, 208).  Blood 
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product use, namely packed red blood cells (PRBC), fresh frozen plasma (FFP), 
cryoprecipitate and platelets in the first 24 hours following admission were recorded. 
Patients were reviewed daily until discharge or death, to record clinical outcomes.  
 
2.4 Outcomes 
2.4.1 Primary outcome 
The primary outcome was the development of infection in critical care.  Due to a lack of 
published infection definitions in Europe, infection was defined using the Centre for 
Disease Control and Prevention (CDC) criteria as a ‘localised or systematic condition 
resulting from an adverse reaction to the presence of an infectious agent(s) or its 
toxin(s) occurring ≥48 hours post admission’ (209). Data on the incidence of infection 
was collected daily from patient records, critical care charts, electronic laboratory 
results and clinical evidence. ED guidelines mandate that prophylactic Co-amoxiclav is 
commenced in all patients with severe injury requiring admission to critical care (unless 
penicillin allergic, when Clarithromycin is prescribed). Currently, there is no definitive 
policy on the recommended duration of prophylactic antibiotics for trauma patients 
admitted to critical care.  The antibiotic prophylaxis is discontinued on the decision of 
either the critical care consultant or microbiologist during daily patient review. 
 
Infection was confirmed by direct observation of purulent exudate, a combination of 
adverse clinical signs e.g. pyrexia or pulmonary infiltrates on a chest x-ray (not 
attributed to acute lung injury) and positive microscopy and culture. Following 
discussion with the critical care consultant microbiologist, criteria for determining 
specific sites of infection were developed using standards from the CDC, American 
College of Surgeons (Surgical site infection)(210)  and adaptations with local clinical 
guidelines (Ventilator associated pneumonia) (Barts Health NHS Trust) (Table 2.2). 
Discrepancies in the diagnosis of an infection were discussed with the consultant 
microbiologist. Colonisation, meaning the presence of microorganisms on skin, mucous 
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membranes, in open wounds, or in secretions but not causing adverse clinical signs or 
symptoms was not diagnosed as infection.  
Table 2.2 Post injury infection site criteria  
Location Criteria 
Bacteraemia Recognised pathogen cultured from one or more blood cultures 
or  
Common skin contaminants cultured from two or more blood 
cultures on two separate occasions within a 48 hour period.  
 
Respiratory infection 
(VAP: not all criteria are 
required for diagnosis of VAP. 
Review of clinical VAP chart in 
patient notes performed daily) 
VAP. Consider if: increased inflammatory markers, pyrexia 
≥38.
0
c or <36.
0
c, Inotrope requirements increased (NA>0.1), new 
onset purulent sputum, increased ETT secretions, increased Fi02 
since previous day, increased PEEP since previous day, new or 
progressive infiltrates on chest x-ray, alternative source of 
infection excluded. Confirmed organisms isolated from sputum. 
 
Pneumonia/RTI. Confirmed organisms isolated from sputum, 
and increase or change in character of sputum with increased 
suction requirements. Other criteria to support the diagnosis: 
pyrexia ≥38
0
c, and/or WBC <4,000 or >12,000mm
3
/increased 
inflammatory markers, and/or worsening gaseous exchange, 
and/or new or progressive infiltrates on chest x-ray.  
 
Urinary tract infection Positive urine culture (collected using appropriate sterile 
technique), and elevated WBC count and inflammatory markers. 
Other criteria to support the diagnosis: pyrexia ≥38
0
c, and/or 
dysuria, and/or abdominal/flank pain (in conscious patients). 
 
Vascular catheter line infection Pathogenic organisms cultured from site swab or catheter tip. 
Other criteria to support the diagnosis: signs and symptoms of 
phlebitis and/or purulent discharge from line site and/or 
pyrexia ≥38
0
c.  
 
Traumatic wound infection At least one of the following: 
Organisms isolated from open, accidental wounds, or  
Organisms isolated from contaminated wounds, following 
cleansing and possibly closure but not requiring surgical 
intervention, or  
Organisms isolated from purulent wound drainage.  
Other criteria to support the diagnosis: pyrexia ≥38
0
c, or 
localised heat, or erythema, or tissue swelling or tenderness. 
 
Surgical site infection (SSI) 
(incisional/organ space) 
Localised heat, or erythema, or tissue swelling or tenderness, or 
pyrexia ≥38
0
c. and at least one of the following: 
Organisms isolated from wound, discharge or tissue of surgical 
incision(s), or 
Surgical wound dehiscence and/or visual evidence of SSI 
diagnosed by a surgeon. 
 
VAP: Ventilator Associated Pneumonia, NA: Noradrenaline, ETT: Endotracheal Tube, PEEP: Positive End Expiratory 
Pressure, RTI: Respiratory Tract Infection, WBC: White Blood Cells  
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2.4.2 Secondary clinical outcomes 
The two main secondary outcomes were mortality and organ failure. Mortality included 
any in-hospital death and was defined as early mortality (≤48 hours) or later mortality 
(>48 hours). The development of organ failure was determined using the Sequential 
Organ Failure Assessment (SOFA) score (211). The sum of the maximum score for each 
organ system was calculated daily (Table 2.3).  Scores were measured from 48 hours 
following admission to exclude multiple organ dysfunction syndrome (MODS), which is 
common after injury and resuscitation (68, 178).  Single organ failure (SOF) was defined 
as a SOFA score of ≥3 in one organ system during each 24 hour period of the critical 
care stay. Multiple organ failure (MOF) was defined as SOF in two or more organ 
systems during each 24 hour period of the critical care stay.   
 
Table 2.3 The Sequential Organ Failure Assessment (SOFA) Score 
Organ system Score 0 Score 1 Score 2 Score 3 Score 4 
Respiratory 
(Pa02/Fi02 
ratio: kPa) 
>53.3 40-53.3 <40 <25.7 <13.3 
Cardiovascular 
(MAP: mmHg) 
≥70 
< 70,  
no inotropes 
Dop. ≤5.0 or  
NE ≤0.05 
mcg/kg/min  
Dop. 5-14 or  
NE ≤0.1 
mcg/kg/min 
Dop. ≥ 14 or  
NE >0.1 
mcg/kg/min 
Central 
Nervous 
System 
(GCS) 
15 13-14 10-12 6-9 <6 
Haematology 
(Platelets 
x10
9
/L) 
>150 101-150 51-100 21-50 ≤20 
Hepatic 
(Bilirubin 
µmol/l) 
0-19 20-32 33-101 102-204 >204 
Renal 
(Creatinine 
µmol/l) 
<110 110-70 171-299 
300-440 or 
<500ml 
urine/24H 
>440 or  
<200ml 
urine/24H 
MAP: Mean arterial pressure; Dop: Dopamine; NE: Norepinephrine. 
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Other clinical outcomes measured included: 
 Venous thromboembolism (VTE). The presence of VTE was confirmed by either 
ultrasound scan (deep vein thrombosis) and/or computed tomography 
pulmonary angiography (CTPA) (pulmonary embolism).  
 Adverse cardiac events, including acute coronary syndrome, supraventricular 
and ventricular arrhythmias and acute onset heart block. These were confirmed 
by clinical staff using Troponin T and I levels, ECG and where appropriate 
echocardiogram. 
 Stroke (either ischaemic or haemorrhagic), confirmed by CT scan. 
 28 day ventilator free days. 
 Critical care length of stay length of stay (LOS) and total hospital LOS. 
 
 
2.5 Blood sampling technique  
2.5.1 Immune system  
Blood tests were taken to measure immune cell counts and evaluate the relationship 
with infection (described in full in chapter 4). On admission and whilst in critical care, 
white blood cell counts (WBC) were measured daily as part of routine inflammatory 
assessment. Blood samples were collected each morning by clinical staff in an EDTA 
tube (Beckton Dickinson, Plymouth, UK), for WBC (leukocyte), neutrophil, monocyte and 
lymphocyte counts. Normal reference ranges are detailed in Table 2.3. 
 
2.5.2 Coagulation system 
Blood tests were taken to measure coagulation after injury and evaluate the 
relationship with infection (described in full in chapter 5). As part of ACIT II, a 30 ml 
research sample of blood was drawn at admission and 24 hours following injury by the 
trauma research team.  Samples for fibrinogen and coagulation factor assays were 
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collected into 4.5ml glass vacutainers (0.109 M buffered sodium citrate, 3.2% - Becton 
Dickinson, Plymouth, UK).    Samples for Factor assay, Protein C (PC) and Protein S (PS) 
were centrifuged with double spun plasma extracted and stored at -80˚C within two 
hours of venepuncture. Normal reference ranges are detailed in Table 2.4. 
 
Table 2.4 Blood sample normal reference ranges 
Test/Factor 
 
Normal range  Test/Factor 
 
Normal range 
WBC 4-11 10
9
/L  Factor IX  
 
58-138 iu/dL 
Neutrophils 2.5-7.5 10
9
/L  Factor X  
 
50-150 iu/dL 
Monocytes 0.2-0.8 10
9
/L  Factor XI  
 
58-148 iu/dL 
Lymphocytes 1-4 10
9
/L  Factor XIII  
 
70-140 iu/dL 
PT 9.4-12.4 seconds  Anti-thrombin  
 
81-119 iu/dL 
APTT 21-31 seconds  Protein C  
 
72-162 iu/dL 
INR 0.9-1.1 iu/dL   Protein S  62-120 iu/dL 
Fibrinogen 1.50-4.50 g/L  PAP 120-700  µg/L 
Factor II  
 
78-117 iu/dL  a2ap  
 
76-126 iu/dL 
Factor  V  
 
66-114 iu/dL  PAI-1 4-43 ng/mL 
Factor VII  
 
50-150 iu/dL  tPA 2–12 ng/mL 
Factor VIII  
 
52-153 iu/dL  D-Dimer <550 ng/mL  
WBC: White blood cells; PT: Prothrombin time; APTT: Activated partial thromboplastin time; PAP: Plasmin 
antiplasmin, a2ap: 2-antiplasmin, PAI-1: Plasminogen activator inhibitor 1, tPA: tissue plasminogen 
activator, DD: D-dimer.  
  
Blood for rotational thromboelastometry (ROTEM, TEM innovations GmbH, Munich, 
Germany) viscoelastic coagulation testing was also taken at 24 hours. ROTEM assesses 
the viscoelastic properties of the blood samples under low shear conditions (212). At 24 
hours post injury it was used to measure the clotting time (CT), clot formation time 
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(alpha angle), clot amplitude at 5 minutes (CA5) and the ultimate strength and stability 
of the clot (maximum clot firmness [MCF]). This sample was drawn into a 2.7ml citrated 
vacutainer (0.109 M buffered sodium citrate, 3.2% - Becton Dickinson, Plymouth, UK) 
and processed in the trauma research laboratory.   
 
2.6 Blood sample analysis 
WBC differential testing required an 18µl sample of blood for fully automated analysis 
using flow cytometry. Samples were processed in the hospital haematology laboratory 
using a Sysmex SE-2100 blood analyser (Sysmex, Milton Keynes). If more than one WBC 
test had been performed in a 24 hour period, the most abnormal results were recorded. 
Normal ranges were defined using the Barts NHS Trust laboratory guidance: Total WBC 
4-11 x109/L, Neutrophils 2.5-7.5 x109/L, Monocytes 0.2-0.8 x109/L and Lymphocytes 1-4 
x109/L. 
 
Blood samples for coagulation analysis were processed by the hospital haematology 
laboratory. This included prothrombin time (PT), activated partial thromboplastin time 
(aPTT), fibrinogen and D-Dimer (DD).  Coagulation factors, PC and PS were measured 
using an automated analyser (Sysmex CA-1500 System, Siemens AG, Germany). Plasma 
activity levels of α2-antiplasmin were assayed using a Sysmex CS2100i automated 
analyser (Siemens AG, Germany).  
 
ROTEM was performed within one hour of blood draw at 37°C on a ROTEM delta 
instrument (Pentapharm GmbH, Munich, Germany) by the ACIT II research team.  20μl 
of recalcitrant (STARTEM) and 20μl of tissue factor derived from rabbit brain (EXTEM) 
were placed into the test cuvette after which 300μl of the blood sample was added. 
Activation with tissue factor was performed to standardize the in vitro coagulation 
process and produce a more rapid result (63). All pipetting steps and the mixing of 
reagents with samples were performed as standard using the automated electronic 
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pipette program. Clotting Time (CT), Clot Amplitude at 5 minutes (CA5), alpha angle (α 
angle) and maximum clot firmness (MCF) were reported for each sample analysed. The 
coefficient of variation for each result is presented in Table 2.5. 
 
Table 2.5 ROTEM repeatability and reproducibility (coefficient of variation %) 
Precision CT Alpha angle CA5 MCF 
Intra-assay 6 1 2 3 
 
Inter-
instrument 
7-13 2-3 2-3 1-3 
 
2.6.1 Enzyme linked immunosorbant assays (ELISA) 
Fibrinolysis is a central component of the coagulation system, and therefore an 
important part of the investigation in aim four. Specific markers of fibrinolysis not 
analysed in the hospital laboratory were quantified using Enzyme Linked 
Immunosorbant Assays (ELISAs). Tissue plasminogen activator (tPA; Asserachrom tPA, 
Diagnostica Stago, Asinieres, France) was assayed by Claire Rourke, Research Assistant, 
Centre for Trauma Sciences. Plasmin-α2-antiplasmin complex (PAP; DRG PAP micro, 
DRG International, Marburg, Germany) and Plasminogen activator inhibitor 1 (PAI-1; 
DRG PAI-1, DRG International, Marburg, Germany) were assayed by Elaine Cole.  
 
2.6.2 PAP ELISA protocol 
1. Reagents were provided in two 96 microtitre wells coated with anti-PAP 
monoclonal antibody, allowed to come to room temperature prior to use. 
2. Plasma samples selected and thawed for five minutes in water bath at 37 0C 
3. 30mL wash solution diluted with 1170 mL de-ionised water 
4. 50 µl (microliters) of Assay Buffer dispensed into each well 
5. 50 µl of standard/ control/sample added to wells and mixed thoroughly 
6. Adhesive cover placed over wells and incubated for 15 minutes at room 
temperature 
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7. Wells washed three times with wash solution using plate washer 
8. 400 µl of enzyme conjugate diluted with 22mL conjugate diluent 
9. 100 µl of enzyme conjugate dispensed into each well 
10. Adhesive cover placed over wells and incubated for 15 minutes at room 
temperature 
11. Wells washed three times with wash solution using plate washer 
12. 100 µl Tetramethylbenzidine substrate solution added to each well 
13. Wells covered with aluminium foil and left at room temperature for 15 minutes 
14. 100 µl of stop solution (sulphuric acid) added to each well 
15. Absorbance of each well read at 450 nm (nanometre) within 30 minutes of step 
14 
 
Calculation of results: 
The absorbance of the ELISA data (optical density=OD) at 450 nm was measured using a 
SIAFR Synergy HT plate reader (BioTek, Winooski, USA).  Concentrations of the samples 
were determined from the standard curve plotted using GraphPad PRISM version 5 
(GraphPad Software Inc, San Diego, CA, USA) in accordance with both the manufacturer 
and GraphPad Prism instruction manual.  Mean absorbance was converted to 
microgram per millilitre (µg/L) using linear regression.  A normal median plasma PAP 
level in healthy adults is 290µg/L. The coefficients of variation for intra-assay 
reproducibility were 2.1-6.3% and for inter-assay reproducibility were 3.5-11%. 
 
2.6.3 PAI-1 ELISA protocol 
1. Reagents were provided in two 96 microtitre wells coated with anti-PAI-1 
monoclonal antibody, allowed to come to room temperature prior to use. 
2. Plasma samples selected and thawed for five minutes in water bath at 37 0C 
3. 30mL wash solution diluted with 1170 mL de-ionised water 
4. 100 µl (microliters) of Assay Buffer dispensed into blank designated wells and 50 
µl of Assay Buffer dispensed into sample designated  wells 
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5. 50 µl sample added to sample designated  wells  
6. 50 µl 1:100 Biotin Conjugate added to all wells and mixed thoroughly 
7. Adhesive cover placed over wells and incubated for two hours at room 
temperature 
8. Wells washed three times with wash solution using plate washer 
9. 100 µl  1:200 diluted Streptavidin-HRP solution added immediately to all wells 
10. Adhesive cover placed over wells and incubated for one hour at room 
temperature 
11. Wells washed three times with wash solution using plate washer 
12. 100 µl Tetramethylbenzidine substrate solution dispensed into each well 
13. Wells covered with aluminium foil and left at room temperature for 10 minutes 
14. 100 µl of stop solution (sulphuric acid) added to each well 
15. Absorbance of each well read at 450 nm within 15 minutes of step 14 
 
Calculation of results: 
Results were calculated using the same methods described for PAP (above), although 
mean absorbance was converted to picogram per millilitre (pg/ml) for PAI-1. The normal 
plasma concentration range of PAI-1 in healthy adults is 4-43 ng/mL (4000-43000 
pg/mL). Coefficient of variation is shown in Table 2.6. 
Table 2.6 Median PAI-1 concentration and coefficient of variation 
Human PAI-1 concentration pg/mL Coefficient of variation (%) 
5000 1.3 
2500 1.7 
1250 1.6 
625 3.0 
313 3.7 
156 5.0 
78 6.4 
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2.7 Data analysis 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, 
San Diego CA USA).  Normal quantile plots were used to test for normal distribution. 
Parametric data were expressed as means (95% Confidence Intervals) and were 
analysed using Students t test or ANOVA. Non-parametric data were expressed as 
medians (Interquartile Range - IQR) and analysed using Mann Whitney U or Kruskal 
Wallis tests.  Categorical variables were analysed using Chi square or Fisher’s exact 
tests. A p value of <0.05 was considered statistically significant.  
 
Multivariate analysis was used to determine statistically independent relationships 
between infection and other variables, using SPSS v21 (IBM Corporation, Armonk, NY, 
USA). Multivariate linear regression was used to analyse continuous dependent 
variables and binary logistic regression for binary dependent variables.  
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CHAPTER THREE THE BURDEN AND DRIVERS OF INFECTION IN SEVERELY 
INJURED PATIENTS  
 
3.1 Introduction 
Contemporary healthcare has placed great emphasis on infection prevention (209, 213), 
yet infections continue to have a major impact on patient outcomes and experience. 
Developing an infection after trauma is associated with increased critical care utilisation 
and hospital stay (73, 83, 136).  Injured patients who survive infection to hospital 
discharge have reported delayed return to functional, psychological and social recovery 
(74). Despite this, infection remains an under-reported and under-recognised cause of 
morbidity in severely injured patients, with much of the evidence derived from 
retrospective reviews (66, 86).   
 
The true incidence of infection for severely injured patients is difficult to ascertain from 
the published evidence as many civilian studies include all trauma patients, regardless 
of acuity or injury severity. Furthermore, studies focus on singular determinants of 
infection such as the association with blood transfusion (111), mechanism of injury (85, 
88) or invasive intervention (99, 214). Therefore the global burden of infection in the 
severely injured population is not widely appreciated, the drivers for its development 
remain unclear, and reports of the effects on clinical outcomes are predominantly 
limited to mortality (67, 86, 108, 109). Overall there is a significant knowledge gap in the 
incidence, drivers and impact of all infections following severe injury in modern civilian 
trauma care.  
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3.2 Study objective and aims 
The overall objective of this study was to characterise the burden of all-cause infection 
in severely injured trauma patients.  
The first aim was to describe the incidence of infection in severely injured patients.  
Secondly to identify which admission, patient or injury characteristics were associated 
with the development of infection.  
Finally, to evaluate outcomes in those patients who developed an infection following 
severe injury.   
 
 
3.3 Methods 
This was a prospective cohort study of severely injured patients presenting to an urban 
major trauma centre over a two year period from February 2011.   
 
3.3.1 Patient selection 
Adult patients (>15 years), admitted to the critical care unit following resuscitation and 
found to have an injury severity score (ISS) of greater than 15, were enrolled. Patient 
recruitment processes have been described in detail in chapter 2.1.2.  
  
3.3.2 Data collection 
Data were collected prospectively on patient demographics, mechanism (blunt or 
penetrating injury), baseline physiology, coagulation and immune cell profiles. Arterial 
blood analysis for base deficit (BD) was performed during the trauma team resuscitation 
on admission as part of normal care processes. BD ≥6mEq/L was utilised to predict the 
presence of hypovolaemic shock on admission to the ED (207, 208). Blood product use 
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was recorded, namely Packed Red Blood cells (PRBC) and Fresh Frozen Plasma (FFP), in 
the first 24 hours following admission. Injury severity was classified using the Injury 
Severity Score (ISS) once all injuries were diagnosed (29).   
 
3.3.3 Outcome measures 
Patients were followed up daily until in hospital death or discharge. The primary 
outcome measure was the presence of infection developed in critical care. Data on the 
incidence of infection and use of prophylactic antibiotics was collected daily from 
patient records, critical care charts, electronic laboratory results and discussion with 
clinicians. Infection was defined using the Centre for Disease Control and Prevention 
(CDC) criteria as a ‘localised or systematic condition resulting from an adverse reaction 
to the presence of an infectious agent(s) or its toxin(s) occurring ≥48 hours post 
admission’ (209). Infection was confirmed by direct observation of purulent exudate, 
adverse clinical signs e.g. pyrexia or pulmonary infiltrates on a chest x-ray (not 
attributable to lung injury) and positive microscopy and culture. Criteria for determining 
specific sites of infection are discussed in chapter 2.4.1. Unless penicillin allergic, 
severely injured patients were given the penicillin combination Co-Amoxiclav for 
antibiotic prophylaxis on admission to critical care. This was reviewed daily and 
discontinued on the advice of the consultant microbiologist.   
 
Other outcomes measured were in-hospital mortality ≥48 hours following admission, 
ventilator free days (VFD), incidence of venous thromboembolism, incidence of adverse 
cardiac events such as new atrial fibrillation or tachyarrythmias, critical care length of 
stay (LOS) and total hospital LOS. The development of organ injury was assessed daily 
using the Sequential Organ Failure Assessment (SOFA) score (211). Single organ failure 
(SOF) is defined as a SOFA score of ≥3 in one organ system during each 24 hour period 
of the critical care stay (176) . Multiple organ failure (MOF) is defined as SOF in two or 
more organ systems during each 24 hour period of the critical care stay.  
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3.3.4 Data analysis 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, 
San Diego CA USA).  Normal quantile plots were used to test for normal distribution. 
Parametric data were expressed as means (95% Confidence Intervals) and were 
analysed using Students t test or ANOVA. Non-parametric data were expressed as 
medians (IQR) and analysed using Mann Whitney U test or Kruskal Wallis.  Proportions 
of dichotomous variables were analysed using Chi square or Fisher’s exact tests 
depending on the size of the sample. A p value of <0.05 was considered statistically 
significant. 
 
Multivariate analysis using SPSS v21 (IBM Corporation, Armonk, NY, USA) was utilised to 
determine statistically independent relationships between admission variables and the 
development of infection. This approach was also used to examine independent 
relationships between infection and other variables on clinical outcomes. Factors 
achieving significance of p<0.15 in univariate analysis were entered into the regression 
models.  Multivariate linear regression was used to analyse continuous dependent 
variables and binary logistic regression for binary dependent variables.  
 
 
3.4 Results  
In the 48 month period 385 trauma patients were admitted to the critical care unit. Of 
these, 300 patients had an ISS >15 and were enrolled into the study. Within the first 48 
hours 29 (10%) patients died, leaving a cohort of 271 available for analysis.  141 patients 
(52%) developed at least one infection during their critical care stay, and there were 304 
infections diagnosed overall, which is an average of two infectious episodes per patient.  
Gram positive bacteria caused the greatest infection burden (Table 3.1).  In blood 
stream infections, the presence of gram positive microbes was approximately two-fold 
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higher, with a similar trend seen in vascular access device, traumatic wound and surgical 
site infections.   
 
Table 3.1 Infections developed during critical care stay 
  
Infection site Number of 
Infections 
n=304 
Gram 
positive 
bacteria 
Gram 
negative 
bacteria 
Fungal 
microbes 
Respiratory 
 
176 (57%) 42% 50% 8% 
Bacteraemia 34 (11%) 62 % 33% 5% 
 
Traumatic wound 
 
45 (15%) 
 
64% 
 
33% 
 
3% 
 
Vascular access 
device 
 
 
27 (9%) 
 
 
64% 
 
32% 
 
4% 
Urinary tract 11 (4%) 27% 73% 0 
 
Surgical site 
infection 
11 (4%) 55% 36% 9% 
     
 
The most prevalent site of infection was the respiratory tract. These infections were five 
times more common than those found in the blood stream and four times more 
common than those affecting traumatic wounds (Table 3.1). The first day of infection 
occurred early in the patients clinical course (Figure 3.1), at day five post injury for the 
majority of patients. 
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Figure 3.1 Day of first infection post injury. Bar chart shows percentage of patients per day of first 
infection.  
 
Different infections presented at different periods after injury.  Respiratory infections 
occurred earliest (Figure 3.2), a median of five days from admission. Median time to 
most other infections was two days later, except SSIs which occurred at median 14 days 
after admission.  
 
 
 
 
 
 
 
 
Figure 3.2 Differing infectious loci present at different times. Box and whisker plots show median and 
interquartile range of respiratory infection at median 5 days vs. blood stream infection at median 7 days 
p<0.001, traumatic wound infection at median 7 days p<0.001, urinary tract infection at median 7 days 
p=0.01, vascular access device infection at median 7 days p=0.03, surgical site infection at median 14 days 
p<0.001.  
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Table 3.2 Patient characteristics, injuries and admission physiology 
 All n=271 No infection 
n=130 (48%) 
Infection       
n=141 (52%)            
p value 
Admission characteristics     
Age† 35 (25-49) 35 (25-28) 35 (26-50) 0.93 
Male 223 (83%) 105 (81%) 119 (85%) 0.57 
Blunt injury 235 (87%) 111 (85%) 125 (89%) 0.52 
Admission injuries     
ISS† 29 (21-36) 26 (20-38) 29 (22-36) 0.14 
AIS Head and neck 4 (1-5) [58%] 4 (1-5) [60%] 4 (1-5) [56%] 0.98 
AIS Face 0 (0-2) [5%] 0 (0-2) [5%] 0 (0-2) [4%] 0.99 
AIS Thorax 3 (1-4) [59%] 3 (1-4) [56%] 3 (0-4) [61%] 0.99 
AIS Abdomen & pelvis  0 (0-2) [12%] 0 (0-2) [13%] 0 (0-2) [11%] 0.95 
AIS Extremity & pelvic ring 2 (0-3) [31%] 1 (0-3) [27%] 2 (0-3) [34%] 0.37 
Admission physiology     
SBP (mmHg)† 122 (89-140) 123 (93-142) 120 (86-139) 0.48 
BD (mEq/L) † 3.4 (0.9-7) 2.1 (-0.8-5.8) 4.3 (2.2-8.4) 0.01 
GCS† 11 (6-15) 12 (5-15) 11 (7-15) 0.69 
APTT (secs) † 25 (23-29) 25 (23-28) 26 (23-29) 0.18 
INR† 1 (1.1-1.2) 1 (1.1-1.2) 1 (1-1.3) 0.97 
Platelets (units) † 206 (156-252) 201 (149-249) 213 (165-256) 0.53 
Fibrinogen (units) † 2 (1.38-2.26) 2 (1.31-2.26) 2 (1.4-2.26) 0.99 
PRBC in first 24 hours† 4 (3-4) 3 (2-4) 4 (3-5) 0.01 
FFP in first 24 hours† 3 (2-3) 2 (1-2) 3 (2-4) 0.02 
Prophylactic antibiotics 239 (88%) 110 (85%) 129 (91%) 0.27 
Duration of prophylactic 
antibiotics (days) † 
3 (2-3) 2 (2-3) 3 (2.3) 0.31 
Values are presented as median (inter quartile range)† or number (%). Values in [square brackets] are % 
AIS  ≥3. ISS: Injury Severity Score; AIS: Abbreviated Injury Scale; BD: Base Deficit; SBP: Systolic Blood 
Pressure; GCS: Glasgow Coma Scale; APTT: Activated Partial Thromboplastin Time; INR: International 
Normalised Ratio; PRBC: Packed red blood cells; FFP: Fresh frozen plasma. 
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Evaluation of admission characteristics revealed that there were no significant 
differences in age, gender, mechanism or severity of injury and prophylactic antibiotic 
use between patients who developed infection, and those who did not (Table 3.2). 
However, severity of shock on admission to hospital was significantly greater in patients 
who subsequently suffered infection (No infection: BD 2.1 mEq/L vs. Infection: BD 4.3 
mEq/L, p=0.01). Similarly, increased blood product requirements in the first 24 hours 
from injury were associated with infection (Table 3.2).   
 
Rates of infection were greater in those who were shocked on admission.  A dose 
dependent relationship was seen between severity of shock and increased percentage 
of infection (Figure 3.3). This increased to two fold higher in the most severely shocked 
cohort.  
 
Figure 3.3 The development of infection is associated with the degree of admission shock. Graph shows 
the percentage of patients with infection in admission base deficit quartiles (mEq/L). Shocked patients 
were significantly more likely to develop infection than non-shocked patients (BD 2-5.9 mEq/L vs. normal 
BD<2 mEq/L - 59% vs. 37%, p<0.01; BD 6-12 mEq/L vs. normal BD<2 mEq/L - 60% vs. 37%, p<0.01; BD>12 
mEq/L vs. normal BD<2 mEq/L - 74% vs. 37%, p<0.01). 
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The time to first infection was also related to shock. Median time to first infection was 
earlier for those in shock compared to those patients not shocked on admission. 
However the most severely shocked patients developed their first infection earliest, on 
average two days prior to the non-shocked cohort (Figure 3.4).  
 
 
  
 
 
 
 
Figure 3.4 Increased shock severity is associated with the timing of infection. Box and whisker plots 
show median and interquartile range of day of first infection according to admission base deficit (mEq/L). 
Median time to first infection was earlier for all degrees of shock compared to those patients not shocked 
on admission. Shocked patients were significantly more likely to develop infection earlier than non-
shocked patients (BD 6-12 mEq/L: 3 days (IQR 3-5) vs. normal BD <6mEq/L: 5 days (IQR 4-7), p<0.01; 
BD>12 mEq/L: 3 days (IQR 3-4) vs. normal BD<2 mEq/L: 5 days (IQR 4-7), p<0.01).  
 
In order to determine an independent relationship between potentially predictive 
admission variables and the development of infection, multivariate logistic regression 
was performed. Factors achieving significance of p<0.15 in univariate analysis were 
entered into the regression model.  Independent variables with univariate significance 
were ISS, BD, PRBC and FFP. After adjusting for the effects of these variables, regression 
analysis showed that only admission BD (p<0.001, OR 1.78, CI 1.48-1.94), was 
independently associated with the development of infection (R2 = 0.63). Therefore, 
shock severity was the only admission variable independently driving the development 
of infection in this cohort of severely injured patients.  
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No differences were seen in unadjusted mortality rates for both groups (9%). However 
incidence of multiple organ failure (MOF) during the critical care stay was significantly 
increased in the infection group compared to those without infection (Infection: MOF - 
35% vs. No infection: MOF - 8%, p<0.01) (Table 3.3).  
 
Table 3.3 Outcomes after infection 
 All n=271 No infection 
n=130 (48%) 
Infection       
n=141 (52%)            
p value 
     
Mortality ≥48H 25 (9%) 12 (9%) 13 (9%) 0.96 
Multiple organ failure  60 (22%) 11 (8%) 49 (35%) <0.01 
VTE 7 (3%) 1 (1%) 6 (4%) 0.40 
Adverse cardiac event 49 (19%) 12 (9%) 37 (26%) 0.05 
VFD† 25 (18-27) 27 (26-28) 19 (12-23) <0.01 
CC LOS† 6 (2-12) 2 (2-12) 12 (8-20) <0.01 
TH LOS† 22 (8-41) 8 (3-17) 33 (25-53) <0.01 
Values are presented as median (inter quartile range) † or number (%).  VFD: Ventilator Free Days; VTE: 
Venous thromboembolism; CC LOS: Critical care length of stay; TH LOS: Total hospital length of stay 
 
There was trend to significance for patients with infection and the development of 
adverse cardiac events (Table 3.3). Further, patients who developed infection had 
significantly fewer ventilator-free days compared to those who did not (Infection: 19 
days vs. No infection: 27 days, p<0.01). In total, patients with infection spent 10 days 
longer in critical care (Infection: 12 days vs. No infection: 2 days, p<0.01) and 25 days 
longer in hospital compared to those without infection (Infection: 33 days, vs. No 
infection: 8 days, p<0.01).  
 
To establish if infection or other variables had an independent effect on outcomes other 
than mortality, multivariate analysis was performed. Factors achieving p<0.15 during 
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univariate analysis were entered into a multivariate regression analysis (Table 3.4). In 
order to find the best statistical correlation between variable and outcome in 
multivariable linear regression, stepwise analysis was chosen with entry at 0.05 and 
removal at 0.10. 
 
Table 3.4 Univariate and multivariate regression analysis of variables associated 
with outcome 
 
Univariate analysis 
  
Multivariate analysis 
 
 
Significant 
variable 
p value  Odds ratio/ 
Beta co-efficient 
95% 
Confidence 
Intervals 
p value R sq 
MOF       
Infection <0.01  15.4 8.20-28.9 <0.01* 0.40 
PRBC 0.13  1.03 0.95 – 1.07 0.65  
       
VTE       
PRBC 0.09  1.00 0.87 – 1.15 0.91 0.27 
Infection 0.05  1.24 0.74 – 5.25 0.09  
       
VFD       
PRBC 0.14  -0.17 -0.39 – 0.09 0.15 0.52 
Infection 0.10  -4.48 -6.76 - -2.13 <0.01*  
       
CCLOS       
Age 0.04  0.41 0.13 – 0.61 0.24 0.45 
ISS 0.05  0.14 -0.01 – 0.30 0.08  
Infection 0.05  13.2 10.0 – 16.4 <0.01*  
       
THLOS       
ISS 0.01  0.33 0.04 – 0.65 0.04* 0.47 
Infection 0.01  31.1 24.0 – 38.2 <0.01* 
 
 
MOF: multiple organ failure, PRBC: packed red blood cells, VTE: venous thromboembolism, VFD: 
ventilator free days, CCLOS: critical care length of stay, ISS: injury severity score, THLOS: total hospital 
length of stay. 
 
Infection was the only factor independently associated with MOF (p<0.01), days on a 
ventilator (p<0.01) and critical care LOS (p<0.01). Both infection (p<0.01) and injury 
severity (p=0.04) had a significant independent relationship with total hospital stay.    
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After adjusting for potentially confounding variables, the development of infection was 
significantly associated with poor clinical outcomes.  
 
3.5 Discussion 
Infection is a substantial burden for severely injured civilian patients admitted to critical 
care. Infection in this cohort was common, with over half of the patients developing an 
infectious episode. Similar to other studies of trauma infections, the respiratory tract 
was most commonly affected; however the majority of infections occurred earlier than 
had previously been appreciated. Shock was the only admission characteristic 
associated with infection in critical care.  Infection also developed more quickly in 
patients who presented in shock.   The development of infection was associated with 
significantly worse outcomes for severely injured trauma patients.  
 
In this cohort of civilian trauma patients, 52% suffered at least one infection following 
injury, which is higher than recently published prospective studies (67, 109). Historic 
prospective evidence reported a 37% incidence of infection (71), although severity of 
injury or physiological status on arrival was not analysed. Early or persistent SIRS 
responses following injury have been associated with infection rates between 41 and 
45% (108, 109). More recent military studies reported infection rates of up to 50% in 
blast injured patients (87, 119), with a mechanism of injury that obviously differs from 
patient in this study.  
 
Whilst the respiratory tract was most commonly affected, the location and types of 
infection developed in this cohort were heterogeneous. Severe infection such as 
ventilator associated pneumonia or bacteraemia may be more clinically significant when 
compared to relatively simple infections such as those affecting the urinary tract. 
However trauma is itself a heterogeneous disease and physiological disturbances as a 
result of injury may lead to an increased risk of infection which would have fewer 
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consequences in a non-injured patient.  For example, whilst relatively innocuous for 
many, infections of the urinary tract are associated with a greater mortality following 
traumatic injury (215). Furthermore due to the number of invasive interventions 
required, managing trauma patients in critical care provides an added risk for infectious 
complications (216). All episodes of confirmed infection, regardless of the location or 
bacteria, have the potential to alter the trauma patients clinical course whilst in critical 
care.  In this study infections resulted in prolonged treatment in critical care, and the 
presence of an infection was strongly associated with increased ventilator dependence 
and the development of multiple organ failure. Other studies of infection in trauma 
patients have also reported increased hospital stays (83), increased healthcare costs 
(73, 136) and delayed longer term recovery (74).  
 
Infection was not only a great burden, but also occurred earlier than expected. Historic 
studies reported infections occurring two to three weeks post hospitalisation (70, 71). 
However, more recent comparable evidence observed first infections occurring at day 
eight post injury (67, 108, 109). In this study, the greatest numbers of first infections 
were diagnosed at day five post injury, suggesting that either the injury or an early 
admission factor may be associated with the development.   
 
The identification of admission shock as the sole driver of infection was surprising.  No 
other patient or injury characteristic such as age, gender or mechanism was statistically 
associated with infection in this severely injured cohort. Previous studies that have 
associated injury severity with infection did not include assessments of shock severity in 
the analysis (24, 66, 111, 136).  The severity of shock also correlated with the timing of 
infection. For those patients who were profoundly shocked on arrival (BD>12 mEq/L), 
infections occurred even earlier, on average at three days from injury.   
 
Haemorrhagic shock may activate pathways that predispose patients to infection. There 
is a high degree of crosstalk between coagulation and inflammation, and early 
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coagulopathy has been associated with the subsequent development of VAP (96, 217) .  
Tissue injury and trauma-related hemorrhage stimulate an inflammatory response 
initially characterised by increased levels of proinflammatory cytokines and activation of 
neutrophils and monocytes (147). However severe trauma is also associated with 
immunosuppression, predominantly seen as anergy in the adaptive immune system T-
lymphocyte populations (144, 152).  Therefore, injury related immunosuppression may 
lead to increased susceptibility to infections. Blood transfusion has also been associated 
with increased infectious episodes (97, 111, 218, 219). While transfusion may have 
effects on immunocompetence, it is possible that these are simply a reflection of the 
underlying degree of shock. Admission shock was the driver for infection in this study 
and improved early shock management may lead to a reduction in the overall burden of 
infection.  
 
The consequences of infection following injury and the impact these have on patient 
outcome and experience are underappreciated in relation to morbidity. Patients who 
developed infection had significantly worse outcomes than those who did not.  While 
there were patient and injury differences, infection was an independent predictor of 
multiple organ failure, ventilator-free days, critical care and hospital stays.  Establishing 
the cause of trauma related infections may help to focus on prevention, and have a 
considerable impact on outcome and patient experience.  
 
This study has a number of limitations. Principally the associative relationship found 
between admission shock and infection, where a potential driver rather than a cause 
was identified. However shock was found to independently predict infection in 
multivariate analysis, and this suggests that the inflammatory and coagulation 
processes which occur early following injury may be implicated. A further limitation is 
that outcomes between the two groups following discharge from hospital were not 
measured. The effects of infection developed in critical care following injury may be far 
reaching. Understanding longer term physical and psychological consequences of 
infection may be important patient and system performance outcome measures. 
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3.6 Conclusion 
The study has shown that infectious complications are a significant burden for severely 
injured patients. Infections occur early in the critical care stay and are associated with 
worsened clinical outcomes. Severity of admission shock was predictive of infection. 
This represents an opportunity for further study into the inflammatory mechanisms 
linked to haemorrhage, and investigation into their relationship with infection.  
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CHAPTER FOUR CHANGES IN IMMUNE CELL COUNTS AFTER SEVERE 
INJURY AND THE RELATIONSHIP WITH INFECTION 
 
4.1 Introduction  
Current concepts suggest that the proinflammatory state after trauma is driven by 
immune cell activation, primarily neutrophils and monocytes (163, 174). A simultaneous 
anti-inflammatory response occurs where neutrophils, monocytes and lymphocytes 
attempt to ‘re-balance’ the pro-inflammatory state (148, 152, 220). Specific evaluation 
of immune cell counts and their relationship with infection in trauma patients is limited. 
The few papers which have reported white cell counts and their effects on outcome 
after injury have shown associations with mortality (108, 153, 162) and MOF (161). This 
evidence suggests that changes to immune cell counts in the days following trauma are 
associated with adverse outcome.  
 
Severe injury may result in suppression or alteration of immune cell responses which 
may predict the development of infection. The research presented in chapter three 
showed that infection after trauma developed in the first week following injury and was 
strongly associated with admission shock. The proposed relationship between 
haemorrhage and inflammation has been previously described however it is unclear if 
hypoperfusion affects immune cell counts following severe injury. Furthermore, 
changes in immune cell counts related to trauma may be predictive of the development 
of infection, and may help in the identification of at risk patients.  
 
4.2 Study objective and aims 
The overall objective of this study was to evaluate early immune cell counts following 
injury and the subsequent development of infection in trauma patients.  
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First, to evaluate the effect of admission hypoperfusion on early leukocyte (WBC), 
neutrophil, monocyte and lymphocyte counts following severe injury.  
Second, to determine if early changes in immune cell counts following severe injury are 
predictive of infection.  
Third, if a predictive relationship is found, to identify an association with the timing and 
site of injury related infection.  
Finally, if early immune cell counts are found to be predictive of infection, to determine 
if they are also predictive of other clinical outcomes, namely multiple organ failure and 
mortality.  
 
 
4.3 Methods 
This was a single centre prospective cohort study of patients presenting to a Major 
Trauma Centre over a twenty four month period from August 2011.  
 
4.3.1 Patient selection 
Severely injured adult patients (>15 years), who met local criteria for full trauma team 
activation and were subsequently admitted to the critical care unit were enrolled. 
Patients who survived beyond 48 hours with an ISS>15, and had complete WBC, 
neutrophil, monocyte and lymphocyte counts from admission to day seven were 
included in the study.   
 
4.3.2 Data collection 
Data were collected prospectively on patient demographics, mechanism (blunt or 
penetrating injury), baseline physiology, admission immune cell profiles and transfusion 
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requirements in the first 24 hours from injury. Admission shock was defined as BD ≥6 
mEq/L (208). Patients were reviewed daily in the critical care unit and followed up to 
discharge or in hospital death.  
 
4.3.3 Immune cell analysis 
WBC, neutrophil, monocyte and lymphocyte counts were collected from the day of 
admission until day seven of the inpatient stay. The need for blood draw was 
determined by the clinical team independent of the study. If patients had several blood 
tests within a 24 hour period, the most abnormal measurements were recorded. The 
procedures for WBC, neutrophil, monocyte and lymphocyte sampling and analysis are 
described in chapter 2.5.1.  
 
4.3.4 Outcome measures 
The primary outcome measure was the development of infection. Each participant was 
reviewed daily for the presence and timing of infection. The Centre for Disease Control 
and Prevention (CDC) criteria was used to define infection occurring ≥48 hours post 
admission (209). Infection was confirmed by direct observation of purulent exudate, or 
a combination of adverse clinical signs e.g. pyrexia or pulmonary infiltrates on a chest x-
ray (not attributed to acute lung injury) and positive microscopy and culture. Further 
detail about the criteria for defining infection is described in chapter 2.4.1. 
 
The main secondary outcomes were the development of multiple organ failure (MOF) 
and mortality. The development of MOF was assessed daily using the Sequential Organ 
Failure Assessment (SOFA) score (176).  Single organ failure was defined as a SOFA score 
of ≥3 in one organ system during a 24 hour period. MOF was defined as single organ 
failure in two or more systems during a 24 hour period.  Patients were followed until 
hospital discharge or death.  For mortality analysis patients surviving to hospital 
discharge were assumed to be alive.   
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4.3.5 Data analysis 
Statistical analysis was performed using SPSS v21 (IBM Corporation, Armonk, NY, USA). 
Students t tests or ANOVA were used to analyse parametric data and Mann Whitney U 
test or Kruskal Wallis test were used for non-parametric data analysis.  The chi-square 
or Fisher’s exact tests were used to analyse proportions and categorical variables. A p 
value of <0.05 was considered statistically significant.  
 
A binary logistic regression model was created to identify factors including immune cell 
counts that were independently associated with infection.  Initially, univariate statistical 
analysis was performed to examine the unadjusted effects of potential predictor 
variables.  Those variables achieving a significance of p<0.15 were added to a 
multivariate logistic model for regression analysis.   
 
 
4.4 Results 
During the study period, 398 patients were admitted following trauma team activation. 
Fourteen (4%) patients died within the first 48 hours. 280 patients had immune cell 
blood tests taken from admission to day seven, therefore this comprised the final 
cohort. Overall, the cohort was predominantly male, severely injured (ISS 29) following 
blunt trauma, with a mean admission BD of 4.3 mEq/L [CI: 1.7-7.6] (Table 4. 1).   
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Table 4.1 Admission characteristics, immune cell counts and hypoperfusion 
 All No shock  
(BD<6 mEq/L) 
Shock  
(BD≥6 mEq/L) 
N 280 176 104 
Male (%) 222 (79) 137 (78) 85 (82) 
Age
†
 39 (26 – 54) 42 (27 – 57) 36 (26 – 51) 
Blunt (%) 259 (93) 165 (94) 94 (90) 
BD (mEq/L)
 †
 4.3 (1.7 – 7.6) 2.3 (0.7 – 4.0) 9.1 (7 – 13.9)** 
ISS
†
 29 (22 – 38) 26 (22 – 34) 34 (24–43)** 
PRBC
†
 0 (0-1) 2 (0-6) 6 (3-11)** 
    
WBCs^    
Day 1 15 (14.2 – 15.8) 14.9 (13.9 – 15.8) 15.3 (13.7 – 16.8) 
Day 2 10.6 (10.1 – 11.1) 10.9 (10.2 – 11.6) 10 (9.2 – 10.9) 
Day 3 10.2 (9.7 – 10.7) 10.6 (9.9 – 11.2) 9.5 (8.6 – 11.3) 
Day 4 9.3 (8.8 – 9.8) 8.8 (8.1 – 9.4) 8.5 (7.7 – 9.3) 
Day 5 9.6 (9.1 – 10.3) 9.9 (9.3 – 10.5) 9 (8.2 – 9.9) 
Day 6 9.3 (9.8 – 10.8) 10.3 (9.7 – 10.9) 10.3 (9.3 – 11.2) 
Day 7 12 (11.4 – 12.7) 11.7 (11 – 12.5) 12.5 (11.3 – 13.7) 
    
Neutrophils^    
Day 1 12.1 (11.4 – 12.8) 11.8 (11.0 – 12.6) 12.6 (11.1 – 14.0) 
Day 2 8.6 (8.1 – 9.0) 8.7 (8.1 – 9.3) 8.3 (7.6 – 9.1) 
Day 3 8.2 (7.7 – 8.6) 8.4 (7.9 – 8.9) 7.8 (7.0 – 8.5) 
Day 4 7.5 (7.0 – 8.0) 7.4 (7.3 – 8.6) 6.8 (6.1 – 7.5) 
Day 5 7.4 (7.0 – 7.8) 7.1 (7.0 – 8.2) 6.8 (6.1 – 7.6) 
Day 6 7.7 (7.3 – 8.2) 7.2 (7.1 – 8.3) 7.7 (6.9 – 8.6) 
Day 7 8.8 (8.3 – 9.4) 8.7 (8.1 – 9.3) 9.0 (8.1 – 10.1) 
    
Monocytes^    
Day 1 1.1 (1.0-1.2) 1.2 (1.0-1.4) 1.0 (0.9-1.2) 
Day 2 0.9 (-0.8-1.0) 1.0 (0.8-1.1) 0.9 (0.8-1.1) 
Day 3 0.7 (0.7-0.8) 0.8 (0.7-0.9) 0.7 (0.6-0.8) 
Day 4 0.7 (0.6-0.7) 0.7 (0.6-0.8) 0.7 (0.6-0.7) 
Day 5 0.8 (0.8-0.9) 0.8 (0.7-0.9) 0.8 (0.8-0.9) 
Day 6 1.0 (0.9-1.1) 1.0 (0.9-1.2) 1.0 (0.9-1.1) 
Day 7 1.2 (1.1-1.3) 1.2 (1.1-1.2) 1.0 (0.9-1.3) 
    
Lymphocytes^    
Day 1 1.8 (1.6 – 2.1) 1.7 (1.5 – 1.9) 2.1 (1.6 – 2.6) 
Day 2 1.0 (1.0 – 1.1) 1.0 (1.0 – 1.1) 1.0 (0.8 – 1.1) 
Day 3 0.9 (0.9 – 1.0) 1.0 (0.9 – 1.1) 0.9 (0.8 – 1.0) 
Day 4 0.9 (0.9 – 1.0) 1.0 (0.9 – 1.0) 0.8 (0.7 – 0.9)* 
Day 5 1.0 (0.9 – 1.1) 1.1 (1.0 – 1.2) 0.8 (0.8 – 1.0)* 
Day 6 1.2 (1.1 – 1.2) 1.2 (1.1 – 1.3) 1.1 (1.0 – 1.2) 
Day 7 1.4 (1.3 – 1.5) 1.5 (1.3 – 1.7) 1.2 (1.1 – 1.4) 
    
Outcomes    
Infection (%) 153 (55) 86 (48) 67 (64)* 
Mortality (%) 24 (9) 14 (8) 10 (10) 
MOF (%) 134 (47) 73 (41) 61 (59)* 
Values expressed as median (IQR)
 †
, Mean (95% CI) ^ or n (%). BD: Base Deficit; ISS: Injury Severity Score; 
PRBC: Packed red blood cells transfused in first 24 hours post injury; WBC: White Blood Cells; MOF: Multi-
organ failure.  Comparisons are between two cohorts: ** p<0.01; * p=0.01. Barts NHS Trust laboratory 
ranges: WBC 4-11 10
9
/L; Neutrophils 2.5-7.5 10
9
/L; Monocytes 0.2-0.8 10
9
/L, Lymphocytes 1-4 10
9
/L.  
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In all patients, the time course changes in immune cell counts after injury followed an 
expected initially pro-inflammatory response in the first 24-48 hours after admission 
(Table 4.1). White cells, neutrophils and monocytes were initially elevated and then 
returned to normal values during this period. Lymphocytes were also initially elevated, 
and then fell to lower than normal values, where patients remained lymphopenic until 
day four post injury. More than half of all of the study population (n=153, 55%) 
developed infection in the first seven days after injury, with median time to first 
infection at day four, principally affecting the respiratory tract.  
 
4.4.1 Admission hypoperfusion and immune cell counts 
On arrival to hospital, 37% of the cohort was in a state of shock (BD≥ 6 mEq/L). For both 
shocked and non-shocked patients, white cell counts were raised on admission, 
returning to normal limits until day seven (Table 4.1). Thereafter, mild leukocytosis was 
observed although there were no differences between groups.  
 
Elevated neutrophils were observed in the first 72 hours for all cohorts. Neutrophil 
counts returned to normal until day seven when neutrophilia was observed, although 
this was not significant (Table 4.1). For all patients, non-significant rises in monocyte 
count were seen in the first two days from injury (Table 4.1). This was followed by a 
return to normal values on days three through five, with non-significant monocytosis 
observed on days six and seven.  
 
Patients in shock were more lymphopenic between days three and five post injury 
(Table 4.1), with significant differences seen between groups on days four and five 
(p=0.01). Further analysis of the non-shocked and shocked cohorts indicated a 
persistent lymphopenia between days three and five in shocked patients, whereas non-
shocked patients were never lymphopenic (Figure 4.1). 
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Figure 4.1. Daily lymphocyte counts and shock. Graph shows mean and 95 confidence intervals (error 
bars). Broken lines indicate normal ranges. Significant differences were seen between cohorts on days 3-
5, with a trend to significance on day 2. Day 1: p=0.46, day 2: p=0.05, day 3: p=0.01, day 4: p=0.01, day 5: 
p<0.01, day 6: p=0.24, day 7: p=0.14.  
 
In summary, significant changes in early immune cell counts in the presence of shock 
were only observed in lymphocyte populations.  
 
4.4.2 Immune cell profiles after severe injury  
Overall white cell counts were above normal in all patients on admission to hospital, 
dropping to normal by day two. Only on day seven post injury was a significant 
difference between those patients with and without infection observed (Figure 4.2A). 
There were no differences in neutrophil counts between patient groups in the first 
seven days following admission. Neutrophilia was present in both groups between 
admission and 72 hours, and then dropped to normal levels until day six, when 
neutrophilia reoccurred (Figure 4.2B).  Monocyte counts were raised on days one and 
two, and again at days six and seven, however significant differences were not seen 
between those who subsequently developed infection and those who did not (Figure 
4.2C).  However, lymphocyte counts differed between the two groups, with 
lymphopenia persisting from day two to six in patients who developed infection (Figure 
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4.2D). In the infection group, lymphocyte counts were significantly lower between days 
three and six, only returning to normal by day seven.   
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Figure 4.2 Early immune cell counts and infection. Graphs show mean and 95 confidence intervals (error 
bars). Broken lines indicate normal ranges. IC: Infectious complications.  
A. Early white blood cell counts and infection. There were no differences in white cell counts between 
patients who developed infection and those who did not, until day 7 (No infection: 10.6 [9.6 – 11.7] vs. 
Infection: 12.4 [11.6 – 13.2], p<0.05). B. Early neutrophil counts and infection. There were no significant 
differences in neutrophil counts between patient groups in the first seven days following admission. C. 
Early monocyte counts and infection. There were no significant differences in monocyte counts between 
patient groups in the first seven days following admission. D.  Early lymphocyte counts and infection. 
Patients who  developed infection were lymphopenic from days 2-6. Day 3 (No infection: 1.1 [1 – 1.3] vs. 
Infection: 0.8 [0.8-1], p<0.001), day 4 (No infection: 1.1 [0.9 – 1.2] vs. Infection: 0.8 [0.8-1], p<0.001),  day 
5 (No infection: 1.2 [0.9 – 1.4] vs. Infection: 0.9 [0.9 - 1], p=0.01), and day 6 (No infection: 1.3 [1.1 – 1.5] 
vs. Infection: 1.1 [1 – 1.2], p=0.01).  
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Table 4.2 Multivariate logistic regression of variables independently associated 
with infection following severe injury 
Univariate analysis Multivariate analysis  
Variable p value  Odds ratio 95% CI p value 
Age 0.51  X   
Gender 0.64  X   
Mechanism 0.72  X   
BD (mEq/L) 0.07*  1.14 1.04 – 1.23 0.02 
ISS 0.47  X   
PRBC 0.56  X   
      
WBC (10
9
/L)      
Day 1 0.31  X   
Day 2 0.22  X   
Day 3 0.67  X   
Day 4 0.62    X   
Day 5 0.66  X   
Day 6 0.38  X   
Day 7 0.02*  1.26 1.00 – 1.58 0.05 
      
Neutrophils 
(10
9
/L) 
     
Day 1 0.32  X   
Day 2 0.18  X   
Day 3 0.63  X   
Day 4 0.50  X   
Day 5 0.81  X   
Day 6 0.40  X   
Day 7 0.05*  0.90 0.70 – 1.16 0.45 
      
Monocytes 
(10
9
/L) 
     
Day 1 0.55  X   
Day 2 0.38  X   
Day 3 0.08*  0.94 0.24 – 3.59 0.93 
Day 4 0.06*  1.40 0.37 - 5.25 0.61 
Day 5 0.49  X   
Day 6 0.73  X   
Day 7 0.58  X   
      
Lymphocytes 
(10
9
/L) 
     
Day 1 0.88  X   
Day 2 0.06*  X   
Day 3 0.01*  0.05 0.01 – 0.34 <0.01 
Day 4 0.01*  0.10 0.02 – 0.48 <0.01 
Day 5 0.03*  0.28 0.07 – 1.06 0.06 
Day 6 0.06*  1.49 0.64 – 3.47 0.35 
Day 7 0.88  X   
CI: Confidence interval; BD: Base Deficit; ISS: Injury Severity Score; PRBC: Packed red blood cells transfused in first 24 
hours post injury; WBC: White Blood Cells. * univariate significant variable entered into the multivariate model. 
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Multivariate logistic regression was performed to identify a potentially predictive 
relationship between admission variables, immune cell counts and infection (Table 4.2). 
Three variables were independently associated with infection after trauma (R2: 0.61). 
The presence of shock on admission had an independent relationship with infection, 
supporting the findings from chapter three. Low lymphocyte counts present on days 
three and four post injury were strongly associated with infection (Day 3: Odds ratio 
0.05, 95% CI 0.01 – 0.34, p<0.01; Day 4: Odds ratio 0.10, 95% CI 0.02 – 0.48, p<0.01). 
These time points correlated with median time to infection. No relationship was found 
between leukocyte, neutrophil or monocyte counts and the development of infection in 
this cohort of patients.  
 
4.4.3 Lymphopenia and the sites and timing of injury related infection.  
The previous analysis demonstrated an independent relationship between lymphocyte 
counts at days three and four following injury and infection. The next aim was to 
evaluate if lymphopenia was predictive of the timing and site of first infection. In order 
to determine a predictive, diagnostic cut- off value for lymphopenia and the 
development of infection, a receiver operating characteristic (ROC) curve was 
constructed (Figure 4.3).  
 
 
 
 
 
 
 
Figure 4.3. ROC curve: Lymphocyte counts predictive of the development of infection.  
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At a lymphocyte count of ≤0.8 109/L, the sensitivity was 67% and the specificity was 80% 
(Table 4.3), therefore this was chosen as the cut-off value for lymphopenia to be 
predictive of infection. The area under ROC (AUROC) was 0.74, which suggests that this 
is a fair test of diagnostic or predictive accuracy. 
 
Table 4.3 Sensitivity and specificity of lymphocyte counts 
Lymphocyte value Sensitivity (%) Specificity (%) 
≤1.0 10
9
/L 78 62 
≤0.9 10
9
/L 60 73 
≤0.8 10
9
/L 67 80 
≤0.7 10
9
/L 41 80 
≤0.6 10
9
/L 27 88 
≤0.5 10
9
/L 17 95 
  
Infection rates were compared between those patients who were never lymphopenic 
(≥0.9 109/L) and those who had experienced at least one episode of lymphopenia. The 
majority of patients (70%) who developed infection had been lymphopenic (≤0.8 109/L) 
at least once after the initial 48 hours post injury time point.  
 
The time to first infection significantly correlated with lymphocyte count changes 
(Figure 4.4). Median time to first infection from admission for patients in the 
lymphopenic cohort was day four, compared to day six for those never lymphopenic 
(p<0.001). 
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Figure 4.4 Median time to first infection. Box and whisker plots show median time to first infection for 
patients who were never lymphopenic compared to those who had at least one episode of lymphopenia. 
Never lymphopenic: 6 days (IQR 5-7) vs. Lymphopenic: 4 days (IQR 3-6), p<0.001. 
 
Lymphopenia also correlated with diagnosis of new infection. There was a fifteen-fold 
increase in percentage of infections diagnosed on day three (Never lymphopenic: 6% vs. 
lymphopenic: 94%, p<0.001), and a six-fold increase on day four for those with 
lymphopenia (Never lymphopenic: 14% vs. lymphopenic: 86%, p<0.001) (Figure 4.5).     
       
 
 
 
 
 
 
 
 
 
Figure 4.5 First day of infection and lymphocyte counts. Bar chart shows percentage of infectious 
episodes per first day of infection between  never-lymphopenic and lymphopenic patients.  Those who 
were lymphopenic at any stage had significantly greater percentage of infection from days 3-7, p<0.001. 
 
87 
 
The most common site of first infection for all patients was the respiratory tract. 
Lymphopenic patients had significantly higher rates of pneumonia on days three and 
four compared to those with normal counts (Day 3 - Normal count: 15% vs. 
Lymphopenia: 51% p<0.01, and Day 4 - Normal count: 22% vs. Lymphopenia: 44% 
p<0.01) (Table 4.4). There was a higher incidence of infection across all sites at these 
time points for lymphopenic patients, however numbers were small and this did not 
achieve statistical significance (Table 4.4).  
 
Table 4.4 The effect of lymphopenia on timing and site of new infections 
 Day 3  Day 4  Day 5  Day 6  Day 7  
L. count 
(10
9
/L) 
≤0.8 >0.8 ≤0.8 >0.8 ≤0.8 >0.8 ≤0.8 >0.8 ≤0.8 >0.8 
           
RTI  20 (51)* 6 (15) 18 (44)* 9 (22) 12 (36) 10 (30) 11 (42) 12 (46) 4 (29) 5 (36) 
BSI 3 (8) 0 4 (10) 3 (7) 1 (3) 2 (6) 0 0 1 (7) 1 (7) 
UTI 0 0 0 0 1 (3) 1 (3) 1 (4) 0 0 1 (7) 
TW 4 (10) 2 (5) 4 (10) 2 (5) 5 (15) 0 1 (4) 0 1 (7) 0 
SSI 1 (3) 0 0 0 1 (3) 0 0 0 0 1 (7) 
VAD 2 (5) 1 (3) 1 (2) 0 0 0 0 1 (4) 0 0 
GI 0 0 0 0 0 0 0 0 0 0 
Total  
daily new 
infection 
(n=153) 
39 
 
 
41 
 
 
33 26 
 
 
14 
Values are presented as  n (%). L. count: Lymphocyte count; RTI: Respiratory tract; BSI: blood stream 
infection, UTI: urinary tract infection, TW: traumatic wound infection, SSI: surgical site infection, VAD: 
vascular access device infection, GI: gastrointestinal infection.  *p<0.001 
 
Overall, changes to lymphocyte counts at days three and four from admission were 
associated with the incidence, timing and site of infection. Lymphopenic patients 
suffered more infections at an earlier time point than patients with normal lymphocyte 
counts. The respiratory tract was the most prevalent site of infection, and lymphopenia 
was associated with significantly more episodes of respiratory infections early in the 
patients clinical course. 
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4.4.4 Lymphocyte counts and outcomes 
Having established the strong association between lower lymphocyte counts and 
infection, the last aim was to evaluate a potentially predictive relationship between 
lymphopenia and  other outcomes, namely multiple organ failure (MOF) and mortality.  
 
4.4.4.i Lymphocyte counts and multiple organ failure 
Overall, 134 (49%) patients developed MOF whilst in critical care. There were significant 
differences in daily lymphocyte counts between the MOF and non MOF cohorts. In 
patients who developed MOF there was a significantly lower lymphocytes on days three 
to six post injury (Table 4.5). 
 
Table 4.5 Daily lymphocyte counts and MOF 
 No MOF  MOF p value 
Lymphocytes 10
9
/L   
Day 2 1.1 (1.0-1.2) 1.0 (0.9-1.1) 0.18 
Day 3  1.0 (0.9-1.1) 0.9 (0.8-1.0) 0.01 
Day 4 1.1 (1.0-1.2) 0.9 (0.8-0.9) <0.01 
Day 5 1.1 (1.0-1.2) 0.9 (0.8-1.0) <0.01 
Day 6 1.3 (1.2-1.4) 1.0 (1.0-1.1) 0.02 
Day 7 1.5 (1.2-1.7) 1.4 (1.2-1.5) 0.24 
Values are presented as mean (95% Confidence Intervals). 
 
Therefore, the relative risk of developing MOF at these time points was calculated  
(Figure 4.6).  
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Figure 4.6 The relative risk of lymphopenia and the association with MOF. Relative risk of MOF (with 
95% Confidence Intervals) is shown for each group.  Broken line represents  a relative risk of 1.  
Lymphopenia vs. normal lymphocyte count on day 3 p=0.20, lymphopenia vs. normal lymphocyte count 
on day 4 p<0.01, Lymphopenia vs. normal lymphocyte count on day 5 p=0.22, lymphopenia vs. normal 
lymphocyte count on day 6  p=0.21.  
 
On days three, five and six, there was a trend to an increased risk of MOF associated 
with lymphopenia. However on day four the risk of developing MOF was significantly 
associated with the presence of lymphopenia (RR: 1.84 95% CI 1.37-2.46, p<0.01).  
 
4.4.4.ii  Lymphocyte counts and mortality 
In the overall study cohort there was a 9% in-hospital (>48 hour) mortality rate.  
Changes in lymphocyte counts were analysed for patients who died compared with 
those who survived to discharge (Table 4.6).  
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Table 4.6 Daily lymphocyte counts and in-hospital mortality 
 Alive to discharge  In-hospital mortality p value 
Lymphocytes 10
9
/L    
Day 2 1.0 (1.0-1.1)  0.9 (0.8-1.1) 0.49 
Day 3  1.0 (0.9-1.1)  0.7 (0.6-0.9) 0.01 
Day 4 1.1 (1.0-1.1)  0.7 (0.6-0.9) <0.01 
Day 5 1.2 (1.0-1.1)  0.8 (0.7-0.9) 0.01 
Day 6 1.2 (1.1-1.3)  1.0 (0.8-1.2) 0.10 
Day 7 1.4 (1.3-1.6)  1.2 (0.9-1.4) 0.22 
Values are presented as mean (95% Confidence Intervals). 
 
Mean lymphocyte counts were lower every day for patients who died, with significant 
differences between groups on days three to five.   Therefore, the relative risk of death 
at these time points was calculated, comparing lymphopenia with normal counts on 
days three to five (Figure 4.7).  
 
 
 
 
 
 
 
 
Figure 4.7 The relative risk of lymphopenia and the association with in-hospital mortality. Relative risk 
of death (with 95%  Confidence Intervals) is shown for each group.  Broken line represents  a relative risk 
of 1.  Lymphopenia vs. normal lymphocyte count on day 3 p=0.01, lymphopenia vs. normal lymphocyte 
count on day 4 p=0.03, lymphopenia vs. normal lymphocyte count on day 5 p=0.02.  
 
Severely injured patients who were lymphopenic between days three and five following 
admission had a statisticially greater risk of death than patients with normal counts. 
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Lymphopenia which had not normalised by day five appeared to be predictive of in 
hospital mortality for severely injured patients.   
 
 
4.5 Discussion 
This study has demonstrated that changes to lymphocyte counts following traumatic 
injury were associated with the development of infection and other outcomes. Overall, 
there was a very high incidence of infection in this cohort of severely injured patients 
with a critical care stay of at least seven days. Decreased lymphocyte counts persisting 
to day five post injury correlated with the presence of hypoperfusion on admission. 
Lymphopenia, persisting to day four post injury, was associated with increased rates of 
infection, which developed earlier and resulted in more episodes of pneumonia. 
Lymphopenia present at day four was associated with the development of MOF, and if 
unresolved by day five post injury was predictive of in-hospital mortality. Low 
lymphocyte counts which do not return to normal levels after severe injury are strongly 
predictive of adverse outcomes.  
 
There was a significant increase in infectious episodes for patients who were shocked 
on arrival, supporting the findings from the research described in chapter three. After 
the initial inflammatory response to injury, there were no differences in WBC, 
neutrophil or monocyte counts regardless of admission hypoperfusion. However 
lymphopenia persisted to post injury day five in those patients who presented in a  
shocked state.  Lowered lymphocyte counts after traumatic injury have been reported 
previously (153, 162, 221), yet the associated presence of hypoperfusion has not been 
described in the evidence. Reasons for lymphopenia after trauma are not fully 
understood and possible suggested causes have included migration of lymphocytes into 
tissues in response to circulating catecholamines (221-223). This may explain the 
relationship between admission shock and lymphopenia observed in this study.  
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Lymphopenia on days three and four post injury was independently associated with 
infection in this severely injured cohort.  Previous evidence suggests that levels of 
lymphocyte populations fall quickly following injury, with values generally returning to 
normal on day three (143, 221). In a non trauma critical care setting, ‘severe’ 
lymphopenia (defined as <0.8 109/L) still present at three days following admission was 
associated with a 53% sepsis rate (160). In trauma patients, tissue damage correlating 
with injury severity has been shown to result in depressed lymphocyte-driven cell 
mediated immunity (157). This may predispose severely injured patients to an increased 
risk of infections. The strong relationship revealed in this study between lymphopenia 
and infection at days three and four may therefore have clinical relevance in the 
prediction of infection.  
 
Lymphopenic patients developed infections earlier than those who were never 
lymphopenic, which was much earlier than previously published (71, 108, 109). In 
common with many trauma studies, pnuemonia and respiratory infections were the 
greatest burden for this severely injured cohort (83, 84, 86, 106). However, the 
presence of lymphopenia resulted in a significantly greater percentage of respiratory 
infection early in their clinical course compared to those who had never been 
lymphopenic. Again, lymphopenia persisting past the initial inflammatory phase may 
help with the identification of patients at risk of early, clinically significant infections. 
 
Lymphopenia was associated  MOF, significantly at day four post injury. Prolonged 
lymphopenia may reflect the development of a persistent inflammatory catabolic 
syndrome, known to be associated with worse outcomes (159). The majority of patients 
who died whilst in hospital remained lymphopenic post injury, and time to death was 
significantly shorter in this cohort. Lymphopenia still present between days three and 
five post injury was predictive of mortality. This supports exisiting historic evidence 
which suggested that lymphopenia maximal at three days post injury resulted in 
increased mortality (153). More recently, failure to normalise lymphopenia within four 
days of injury was strongly associated with in-hospital death (162). My findings support 
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this evidence and add that lymphopenia persisting to day five post injury is predictive of 
in-hospital mortality in severely injured patients.  
 
This study has demonstrated a strong relationship between lymphopenia and the 
development of trauma infections, but does have limitations. Firstly, cell counts were 
measured for seven days post injury, and sampling for a longer time period may have 
yielded further results in patients who developed infection at a later stage in their 
clinical course. Secondly, 280 patients is a relatively small cohort. However in order to 
evaluate immune cell changes in during the inflammatory response to severe injury, 
patients with ISS>15 requiring critical care intervention were most likely to have 
experienced this. A further limitation of the study is that whilst it demonstrated a strong 
association between lymphopenia and infection, the mechanistic link between the two 
was not investigated, and requires further characterisation. 
 
 
4.6 Conclusion 
This is the first study to have evaluated daily immune cell counts for a full week post 
injury and their relationship with infection. Lymphopenia which failed to normalise by 
day three or four after injury was strongly associated with the development of infection 
after trauma. Patients with persistently decreased lymphocyte counts also developed 
infections more quickly and suffered greater rates of pnuemonia. Prolonged 
lymphopenia after injury may have utility in identification of patients at risk of infection 
and other adverse outcomes. This may represent a potential clinical indicator for early 
intervention and reduction in infection.  
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CHAPTER FIVE COAGULATION SYSTEM CHANGES AND SUSCEPTIBILITY 
TO INFECTION IN TRAUMA PATIENTS 
 
5.1 Introduction 
Coagulation changes are common after severe injury (193), and major haemorrhage 
results in early acute traumatic coagulopathy (ATC) in approximately one quarter of 
patients (183). Coagulation and inflammation are closely linked, with common proteins 
and pathways allowing crosstalk between the two systems (190).   In particular, the 
anticoagulant Protein C (PC) and fibrinolytic Plasminogen-Plasmin system, both 
implicated in the development of ATC, have strong immune regulatory properties (187, 
224).  Both proteins activate intracellular signalling pathways through their own cell 
surface receptors and activate immune cell mechanisms (21, 141, 225).   
 
The importance of this crosstalk has been recognised in critically ill patients, where 
decreased protein C levels have been associated with the subsequent development of 
sepsis (226-229).  Similarly, elevated plasmin levels have been associated with the 
development of gram negative bacterial infections in non-trauma critical care patients 
(230).  It is possible therefore that change in these protein levels due to activation of 
anticoagulation and fibrinolytic pathways may lead to subsequent immunological 
deficits which leave trauma patients at risk of infection. The relationships between 
coagulation changes and the subsequent development of infection have not been 
established in trauma patients.  Understanding these relationships may lead to 
opportunities for new therapeutic approaches in reducing the burden of infection. 
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5.2 Study objective and aims 
The overall objective of this study was to define the relationship between the state of 
the coagulation system after injury and the subsequent development of infection.  
First, to determine if the status of the coagulation system at 24 hours after injury was 
associated with the subsequent development of infection.  
Secondly, to identify if there were any differences in the location of infection and 
infecting organisms associated with post-injury changes in the coagulation system.   
Finally to examine clinical outcomes in patients who developed infection in the 
presence of coagulation changes.  
 
 
5.3 Methods 
5.3.1 Patient selection 
All adult trauma patients (>15 years) who met the local criteria for full trauma team 
activation were eligible for enrolment into the ACIT II study (Activation of Coagulation 
and Inflammation in Trauma). Inclusion and exclusion criteria for ACIT II are described in 
detail in chapter 2.1.2. Patients who were subsequently admitted to critical care were 
enrolled into this study over a one year period.  
 
5.3.2 Data Collection  
Data were collected prospectively on patient demographics, mechanism of injury (blunt 
or penetrating force), baseline physiology and immune cell profiles.  Arterial blood 
analysis for base deficit (BD) measurement was performed during the trauma team 
resuscitation on admission as part of normal processes of care. Blood product use in the 
first 24 hours following admission, namely Packed Red Blood cells (PRBC), Fresh Frozen 
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Plasma (FFP), Platelets and Cryoprecipitate, were documented. Injury severity was 
classified using the Injury Severity Score (29) once all injuries were accounted for. 
 
5.3.3 Blood sampling technique  
At 24 hours following admission a 20 mL research sample of blood was drawn along 
with the standard trauma laboratory tests (as per ACITII protocol). This time period was 
chosen to allow for completion of resuscitation and haemorrhage control processes. 
Samples for fibrinogen and coagulation factor assay were collected into 4.5ml glass 
vacutainers (0.109 M buffered sodium citrate, 3.2% - Becton Dickinson, Plymouth, UK).  
Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and D-
Dimer (DD) were processed by the hospital laboratory along with a full blood count 
(FBC), neutrophils, monocytes and lymphocytes.  Samples for Factor assay, PC and 
Protein S (PS) were centrifuged with double spun plasma extracted and stored at -80˚C 
within two hours of venepuncture.  Blood for ROTEM analysis was drawn into a 2.7ml 
citrated vacutainer (0.109 M buffered sodium citrate, 3.2% - Becton Dickinson, 
Plymouth, UK) and processed in the trauma research laboratory.   
 
5.3.4 Blood sample analysis 
An automated analyser (Sysmex CA-1500 System, Siemens AG, Germany) was used to 
measure coagulation factors, PC and PS. Plasma activity levels of α2-antiplasmin were 
assayed using a Sysmex CS2100i automated analyser (Siemens AG, Germany). Enzyme 
linked immunosorbant assays were used to quantify tissue plasminogen activator (tPA; 
Asserachrom tPA, Diagnostica Stago, France) and plasmin-α2-antiplasmin complex (PAP; 
DRG PAP micro, Germany). Thromboelastometry was performed within one hour of 
blood draw at 37°C on a ROTEM delta instrument (TEM Innovations GmbH, Munich, 
Germany Clotting Time (CT), Clot Amplitude at 5 minutes (CA5), alpha angle (α angle) 
and maximum clot firmness (MCF) were reported for each sample analysed. More 
detailed description of sample analysis is provided in Chapter 2.6. 
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5.3.5 Outcome measures 
The primary outcome was infection. This was defined using the Centre for Disease 
Control and Prevention (CDC) criteria as a ‘localised or systematic condition resulting 
from an adverse reaction to the presence of an infectious agent(s) or its toxin(s) 
occurring ≥48 hours post admission’ (209). Infection was confirmed by direct 
observation of purulent exudate, adverse clinical signs e.g. pyrexia or pulmonary 
infiltrates on a chest x-ray and positive microscopy and culture. More detailed methods 
for the diagnosis of infection are described in chapter 2.4.1.  
 
Secondary outcomes measured were in-hospital mortality, the development of organ 
failure (measured using the Sequential Organ Failure Assessment (SOFA) score), critical 
care length of stay (LOS) and total hospital LOS. Single organ failure (SOF) was defined 
as a SOFA score of ≥3 in one organ system during 24 hour period. Multiple organ failure 
(MOF) was defined as SOF in two or more organ systems during a 24 hour period (176).  
Organ failure scoring systems are described in more detail in chapter 2.4.2.  Patients 
were followed until hospital discharge or death.  For mortality analysis patients 
surviving to hospital discharge were assumed to be alive.   
 
5.3.6 Data analysis 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, 
San Diego CA USA) and SPSS v10.0.5 (IBM Corporation, Armonk, NY, USA) for 
multivariate analysis. Non-parametric data were expressed as median (interquartile 
range). Parametric data were expressed as mean (95% confidence intervals).  Mann 
Whitney U test or Kruskal Wallis test were used to analyse non-parametric data, and 
Students t test or ANOVA for parametric data.  Percentages were analysed using Chi 
square or Fisher’s exact tests.  A p value of <0.05 was considered statistically significant. 
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5.4 Results 
One hundred and fifty eight patients were recruited to the study over a twelve month 
period in accordance with the inclusion criteria. Patients who developed infection were 
older, more likely to have sustained blunt trauma and were more severely injured than 
those who did not develop infection.   The presence of hypoperfusion on admission was 
significantly associated with infection (Table 5.1). 
 
Table 5.1  Admission characteristics  
 All   
(n=158) 
No infection  
(n=87) 
Infection  
(n=71) 
Male 134 (85%) 73 (55%)  61 (45%) 
Age^ 35 (24-54) 32 (24-42) 44 (25-59)* 
Blunt injury 133 (84%) 67 (77%) 66 (93%) 
ISS^ 15 (9-29) 15 (9-18)  25 (15-33)** 
    
BD mEq/LϮ 2.5 (1.8–3.1) 1.1 (0.3–1.8) 4.2 (3.3-5.2)** 
SBP <90 mmHg 25 (16%) 13 (15%) 12 (17%) 
PRBC in 1st 24HϮ 1 (0.61.1) 1 (0.5-1.8) 2 (1.2-2.7) 
FFP in 1st 24HϮ 0.5 (0.3-0.7) 1 (0.2-1.4) 1 (0.6-1.6) 
Cryo in 1st 24HϮ 0 (0-0.1) 0 (0-0.2) 0 (0-0.3) 
Plts in 1st 24HϮ 0 (0-0.1) 0 (0-0.3) 0 (0-0.3) 
    
WBC 109/LϮ 9.7 (9.0-10.1) 9.6 (8.8-10.3) 9.6 (8.7-10.4) 
Neutrophils 109/LϮ 7.5 (7.0-7.9) 7.2 (6.5-7.9) 7.7 (7.0-8.5) 
Monocytes 109/LϮ 1.1 (1.0-1.2) 1.2 (1.0-1.4) 1.0 (0.9-1.1) 
Lymphocytes 109/LϮ 1.2 (1.1-1.3) 1.3 (1.2-1.5) 1.0 (0.8-1.1)* 
Values are ^median (inter quartile range), 
Ϯ
mean (95% Confidence Intervals) or number (%).ISS: Injury 
Severity Score; BD: Base Deficit; SBP: Systolic Blood Pressure; PRBC: Packed Red Blood Cells; FFP: Fresh 
Frozen Plasma; Cryo: Cryoprecipitate; Plts: Platelets; WBC: White Blood Cells. Barts health laboratory 
ranges: WBC 4-11 10
9
/L; Neutrophils 2.5-7.5 10
9
/L; Monocytes 0.2-0.8 109/L; Lymphocytes 1-4 10
9
/L.        
p value: comparison of two groups. * p<0.05; ** p<0.01 
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Immune cell counts at 24 hours after injury were analysed for those who subsequently 
developed infection compared to those who did not. WBC, neutrophil and monocyte 
counts were similar and within normal ranges for both groups of patients. However, 
there was a small but statistically significant difference in lymphocytes between groups 
(Table 5.1). Patients who subsequently developed infection had lower lymphocyte 
counts at 24 hours post injury (No infection: 1.3 [1.2-1.5] vs. Infection: 1.0 [0.8-1.1], 
p=0.03).   Overall, there did not appear to be an obvious exhaustion of immune cells at 
this time-point after injury which might explain a subsequent susceptibility to infection. 
However, the trend to lymphopenia in those who developed infection supports the 
findings from the cohort study described in chapter four.  
 
Analysis of the global status of coagulation was initially carried out using functional 
thromboelastometry testing (ROTEM). At 24 hours, all ROTEM parameters were similar 
in both groups with no statistical differences noted (No Infection vs. Infection – CT: 
67sec vs. 62sec, CA5: 45mm vs. 44mm, alpha angle: 70.7mm vs. 70.5mm, MCF: 61mm 
vs. 60mm, all not significant).   Laboratory tests of coagulation at 24 hours post injury 
(PT, APTT) differed between the two groups but remained within normal ranges (No 
infection vs. Infection - PT: 11.5sec vs. 12sec, p=0.06; APTT: 28.6sec vs. 32.7sec, p=0.04). 
Therefore, there were no obvious differences in functional clot formation at 24 hours 
between patients who subsequently developed an infection and those who did not.   
 
Despite these normal functional clotting profiles there were significant underlying 
changes in the levels of the coagulation system constituents. Procoagulant factor levels 
were significantly lower in the infection group, although average values remained 
within the normal ranges (Table 5.2).   Excluding factor VII, where levels were higher but 
not statistically significant, patients who developed infection had 24-hour procoagulant 
protein levels around 12% lower than those who did not (varied between factor VIII 
6.4% and factor II 16.2%). 
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Table 5.2 Coagulation factors and infection 
Test/Factor 
 
Normal range No infection Infection  
Fib  1.50-4.50 g/l 2.96 (2.82-3.10) 2.67 (2.47-2.88) **  
 
II  
 
78-117 iu/dL 76.4 (72.1-80.7) 64 (59.3-68.6) *
* 
V  
 
66-114 iu/dL 87 (80.6-93.4) 75.2 (69.1-81.30)  
VII  
 
50-150 iu/dL 62.1 (56.8-67.4) 62.9 (55-70.8)  
VIII  
 
52-153 iu/dL 155.8  (145-166.6) 145.8 (132.2-156.4) ** 
IX  
 
58-138 iu/dL 108.2 (103.1-113.2) 99.2 (93.7-104.8) ** 
X  
 
50-150 iu/dL 82.2 (77.7-86.7) 70.8 (66.3-75.3) * 
XI  
 
58-148 iu/dL 75 (70.8-79.2) 63.4 (59.4-67.4) ** 
XIII  
 
70-140 iu/dL 89.2 (84.2-94.1) 80.2 (74.2-86.1) * 
AT  
 
81-119 iu/dL 89.5 (85.5-93.6) 78.8 (74.5-83.1) * 
PC  
 
72-162 iu/dL 83.3 (78.5-88.1) 70.2 (65.4-74.9) ** 
PS  62-120 iu/dL 86.4 (81-91.8) 75.8 (70-81.6)  
PAP 120-700  µg/L 3324 (2412-4236) 6156 (4397-7916) ** 
 
a2ap  
 
76-126 iu/dL 95.6 (90-100.9) 84.4 (79.5-89.2) * 
PAI-1 4-43 ng/mL 33.2 (24.3-42.2) 32.7 (23.9-41.5)  
tPA 2–12 ng/mL 11.3 (9.2-13.5) 14.4 (9.4-19.5)  
DD <550 ng/mL  5422 (4242-6602) 9383 (7169-11600)
  
** 
 
 Values are expressed as mean (95% Confidence intervals). Fib: fibrinogen, AT: Anti thrombin III, PC: 
Protein C, PS: Protein S, PAP: Plasmin antiplasmin, a2ap: 2-antiplasmin, PAI-1: Plasminogen activator 
inhibitor 1, tPA: tissue plasminogen activator, DD: D-dimer. *p<0.05; ** p=0.01 
 
At 24 hours post injury, patients who went on to develop infection had depleted levels 
of anticoagulants Antithrombin III (11.9% reduction compared to no infection, p=0.04) 
and Protein S (12.2% reduction compared to no infection, p=0.09) (Table 5.2). Protein C 
101 
 
<64 64-75 76-94 >94
0
20
40
60
80
*
24 hour PC levels (iu/dL)
P
at
ie
n
ts
 w
it
h
 in
fe
ct
io
n
 (
%
)
(PC) was significantly lower in the infection group (No infection: 83.3 iu/dL, vs. Infection: 
70.2 iu/dL, p=0.01), (Table 5.2).  Further analysis revealed a dose dependent increase in 
the development of infection as levels of PC decreased (Figure 5.1).  
  
 
 
 
 
 
 
 
Figure 5.1 Percentage of patients with infection in 24 hours PC quartiles.  Graph shows percentage of 
patients with infection in 24 hour PC quartiles (iu/dL).In <64iu/dL: 59% of patients developed infection, 
64-75iu/dL: 57%,  76-94iu/dL: 26% and  >94iu/dL: 22%; p<0.001 (chi squared test for trend). 
 
For fibrinolytic pathways at 24 hours, levels of Alpha 2 antiplasmin (a2ap) and 
Plasminogen activator inhibitor 1 (PAI-1) remained within normal ranges for both 
groups of patients (Table 5.3). D-Dimer levels were significantly raised (No infection: 
5422 ng/mL, vs. Infection: 9383 ng/mL, p=0.01), and tissue plasminogen activator (tPA) 
levels were 27.4% higher in the infection group although this was not statistically 
significant (Table 5.3). However, plasmin antiplasmin (PAP) levels were almost 50% 
higher in patients who developed infection (No infection: 3324 µg/L, vs. Infection: 6156 
µg/L, p=0.01). Furthermore, the proportion of patients who went on to develop 
infection increased with plasmin generation (Figure 5.2).  
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Figure 5.2 Percentage of patients with infection in 24 hour PAP quartiles.  Graph shows percentage of 
patients with infection in 24 hour PAP quartiles (µg/L). In <1261µg/L: 33% of patients developed infection, 
1262-2271µg/L: 31%, 2272-3830µg/L: 54% and >3830µg/L: 60%; p<0.001 (chi squared test for trend). 
 
Most infections occurred in patients who had significantly raised levels of PAP complex 
with 65% of total infections observed in the two highest PAP quartiles (≥2272 µg/L).   
 
Multivariate logistic regression analysis was performed to identify the coagulation 
factors that were independently associated with infection.  The inter-connectivity of the 
coagulation and fibrinolytic system could have potentially complicated the analysis.  
Therefore factors found to be significant in univariate analysis were selected as 
representatives of their primary pathway and included in the model (II - procoagulant; 
PC – anticoagulant; PAP – fibrinolysis; Fibrinogen - substrate).  In multivariate analysis 
only PC (Odds ratio 0.97, 95% CI: 0.97-0.99, p=0.004) and PAP (Odds ratio 1.01, 95% CI: 
1.01-1.03, p=0.006) were independently associated with infection (R Squared=0.58). 
Thus at 24-hours after injury, patients who subsequently develop infections had 
independent differences in levels of coagulation components known to have important 
roles in immunological activity. 
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The majority of infections, both aerobic and anaerobic, occurred in patients who had 
significantly depleted levels of PC (≤75 iu/dL) at 24 hours (76% anaerobic bacteria and 
74% aerobic bacteria), with most infections found in sputum, traumatic wounds and 
blood cultures (Table 5.3). This trend continued with gram positive and gram negative 
infections, where higher numbers of both were seen in the two lowest PC quartiles 
(Table 5.3).  
 
Table 5.3        24 hour Protein C levels and outcomes 
 24H PC  
<64 
24H PC  
64-75 
24H PC  
76-94 
24H PC  
>94 
N=158 42 42 38 36 
Patients with infection: n = 71 25 (59%) 24 (57%) 14 (36%) 8 (22%) 
Source of infection     
Sputum (n= 65) 27 (42%) 22 (34%) 11 (16%)  5 (8%)*  
Traumatic wound (n = 51) 19 (37%) 19 (37%) 9 (17%) 4 (9%)* 
Urine (n = 14) 9 (64%) 3 (22%) 1 (7%) 1 (7%)* 
IV line (n=8) 4 (50%) 3 (37%) 1 (13%) 0 (0%)* 
Blood culture (n=20) 13 (65%) 6 (30%) 0 (0%) 1 (5%)* 
     
Microbes     
Gram positive (n=71) 27 (38%) 22 (31%) 10 (14%) 12 (17%)* 
Gram negative (n=94) 25 (27%) 49 (52%) 18 (19%) 2 (2%)* 
Aerobic (n = 39) 15 (38%) 14 (36%) 8 (21%) 2 (5%)* 
Anaerobic (n = 109) 37 (34%) 46 (42%) 12 (11%) 14 (13%)* 
Fungal (n = 6) 3 (50%) 2 (33%) 1 (17%) 0 (0%)* 
     
Outcomes     
Mortality  3 (7%) 1 (2%) 2 (5%) 3 (8%) 
Multiple organ failure 17 (40%) 13 (31%) 5 (13%) 7 (19%)* 
Critical care LOS (days) 7 (4-12) 10 (5-13) 5 (2-8) 6 (2-11) 
Hospital LOS (days) 13 (6-26) 13 (6-24) 11 (4-19) 6 (3-16)* 
Values are shown as median (inter quartile range) or number (%).  LOS: Length of Stay. * p <0.01, chi 
squared test for trend. 
 
Similarly, more anaerobic and aerobic infections developed where plasmin levels had 
increased (PAP≥2272 µg/L: 70% anaerobic infection and 72% aerobic infection) (Table 
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5.4). Greater numbers of both gram positive and gram negative infections were seen in 
the highest PAP quartiles (Table 5.4).  
 
Table 5.4         24 hour Plasmin-Antiplasmin levels and outcomes 
 24H PAP 
<1261 
24H PAP 
1262-2271 
24H PAP 
2272-3830 
24H PAP 
>3831 
N=158 40 39 39 40 
Patients with infection: n = 71 13 (33%) 12 (31%) 21 (54%) 25 (63%) 
Source of infection     
Sputum (n = 65) 9 (14%)  5 (8%) 17 (26%) 34 (52%)* 
Traumatic wound (n = 51) 9 (18%) 5 (10%) 22 (43%) 15 (29%)* 
Urine (n = 14) 3 (22%) 2 (14%) 2 (14%) 7 (50%)* 
IV line (n = 8) 1 (13%) 0 (0%) 4 (50%) 3 (37%)* 
Blood culture (n = 20) 3 (15%) 2 (10%) 6 (30%) 9 (45%)* 
     
Microbes     
Gram positive (n=71) 11 (15%) 9 (13%) 26 (37%) 25 (35%)* 
Gram negative (n=94) 16 (17%) 9 (10%) 24 (25%) 45 (48%)* 
Aerobic (n = 39) 9 (23%) 2 (5%) 14 (36%) 14 (36%)* 
Anaerobic (n = 109) 17 (16%) 16 (14%) 24 (22%) 52 (48%)* 
Fungal (n = 6) 0 (0%) 0 (0%) 3 (50%) 3 (50%) 
     
Outcomes     
Mortality 3 (8%) 0 (0%) 1 (3%) 5 (13%) 
Multiple organ failure 11 (28%) 8 (21%) 12 (31%) 12 (30%) 
Critical care LOS (days) 5 (3-15) 4 (2-8) 7 (3-9) 8 (2-14) 
Hospital LOS (days) 8 (3-17) 6 (4-16) 15 (7-23) 19 (7-30)* 
Values are shown as median (inter quartile range) or number (%).  LOS: Length of Stay. * p <0.01, chi 
squared test for trend. 
 
Overall mortality rates were low, (n=9, 6%). Mortality was higher with increased 
plasmin generation at 24 hours (Table 5.4) however this increase did not correlate with 
lower levels of PC. The incidence of multiple organ failure increased with depleted levels 
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of PC (Table 5.3, p<0.01), and although not statistically significant, rates of MOF also 
increased with raised levels of PAP (Table 5.4).   
 
Critical care length of stay was greater in the lower PC quartiles (PC ≤75 iu/dL: 17 days 
vs. PC >75 iu/dL: 11 days, ns) and also with plasmin generation (PAP <2271 µg/L: 9 days 
vs. PAP ≥2272 µg/L: 15 days, ns).  Significant differences were seen in total hospital 
length of stay in depleted PC quartiles (PC ≤75 iu/dL: 26 days vs. PC >75 iu/dL: 17 days, 
p=0.04) (Figure 5.3A) and for increased PAP levels (PAP <2271 µg/L: 14 days vs. PAP 
≥2272 µg/L: 34 days, p=0.02) (Figure 5.3B).   
 
 
A        
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Figure 5.3. Coagulation changes and length of stay. A. Total length of hospital stay in 24 hour PC 
quartiles. Box and whisker plots show median, interquartile range and adjusted range of hospital length 
of stay of patients with infection in 24 hour PC quartiles (iu/dL). <64iu/dL: 13 days, 64-75iu/dL: 13 days, 
76-94iu/dL: 11 days and >94iu/dL: 6 days; p=0.04 (Kruskal Wallis test). B. Total length of hospital stay in 
24 hour PAP quartiles. Box and whisker plots show median interquartile range and adjusted range of 
hospital length of stay of patients with infection in 24 hour PAP quartiles (µg/L). <1261µg/L: 8 days, 1262-
2271µg/L: 6 days, 2272-3830µg/L: 15 days and >3830µg/L: 19 days; p=0.02 (Kruskal Wallis test). 
 
5.5 Discussion 
This prospective study has examined the association between coagulation factor 
changes and infection in a trauma setting. Patients who subsequently developed 
infections had normal white cell and functional coagulation profiles at 24 hours, but 
showed depletion of PC and increased levels of PAP. These findings characterise a 
patient group at increased risk of infection and may also represent an opportunity for 
therapeutic intervention to improve outcomes after trauma. 
 
Coagulopathy following severe injury is not uncommon and has been shown to have an 
adverse effect on morbidity and mortality (96, 231). ATC characterised by systemic 
anticoagulation with depleted levels of PC, and global fibrinolysis presents early in the 
patient course following injury (21, 63, 183, 188). Early activation of PC may lead to a 
subsequent depletion, and these patients are known to develop a late hypercoagulable 
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state and thrombotic risk (232, 233).  PC depletion and sepsis is well described in 
studies examining outcomes following critical illness (227, 228, 234).  In trauma 
patients, depletion of PC up to the first 12 hours after injury was associated with a 
propensity to nosocomial lung infection (217). The findings of this study add to the 
evidence and demonstrate that patients who do not recover their plasma PC levels at 
24 hours post injury are significantly more likely to develop HAI, with lower PC levels 
correlating with higher rates of both gram positive and gram negative infections.  
 
The coagulation system was traditionally viewed as entirely separate from the immune 
response. However, it is now suggested that coagulation and innate immunity have co-
evolved and that following tissue injury their cross talk results in simultaneous 
activation (190). Non-trauma evidence has described the important role that the 
coagulation system plays in the host response to infection. D-dimers and PAP were 
found to be raised early in non-trauma sepsis, with a further increase in levels once 
severe sepsis was confirmed (235). These changes were independent of causative 
infectious pathogens with both gram positive and gram negative organisms associated 
with increased fibrinolysis. Furthermore, in non-trauma bacterial infections, PAI-1 and 
a2ap, both activators of plasmin, were reported to increase dispersal of fibrin clots thus 
facilitating bacterial spread (236). In trauma patients, this study adds to the evidence by 
revealing a strong association between activation of the plasminogen-plasmin system at 
24 hours post injury and an increased risk of infection. 
 
 The development of infectious complications was associated with increased total 
hospital stays. Hospital length of stay was also strongly associated with PC depletion 
and increased plasmin-antiplasmin levels at 24 hours.  Many factors affect hospital stay, 
however if these coagulation changes are causative, this may represent an opportunity 
for clinical intervention to reduce both the incidence of infection and hospital stays, and 
improve the patient experience.  
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This study has a number of limitations. Whilst I have demonstrated an association 
between coagulation changes and infection, the mechanistic, causal link between the 
two was not established, and requires further characterisation.  Secondly, the selection 
of variables for regression analysis could have potentially impacted on the results.  The 
independent variables within each pathway may have been highly correlated to one 
another therefore significant representatives of each were chosen. Forwards (addition) 
and backwards (elimination) stepwise regression technique might have been 
considered, which is useful for selecting and standardising a small set of the most 
significant predictor variables (237). Alternatively, variables may have been selected and 
reduced using Lasso regression (238), however this would have required advanced 
statistical expertise. Finally, this study did not specifically examine the acute phase of 
care to establish which interventions may have contributed to low PC and high PAP 
levels at 24 hours. However severity of injury was much higher in those who developed 
infection, as was the degree of admission hypoperfusion. This may reflect the level of 
tissue damage and haemorrhage present in these patients, which could explain the 
coagulation differences experienced by the infection cohort. Further research 
examining early interventions for trauma patients known to be or suspected of bleeding 
and the effect on infection is warranted.  
 
5.6 Conclusion 
Infection following severe injury develops in patients who have an abnormal 
coagulation profile at 24 hours, specifically those with in anticoagulant and fibrinolytic 
pathways. Decreased levels of PC and increased plasmin generation and other 
fibrinolytic markers at 24 hours post injury were predictive of infection.   Early 
management of haemorrhage and potential coagulopathy may improve outcomes for 
this population, and this may represents an opportunity for further research. 
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CHAPTER SIX THE EFFECT OF TXA ON THE DEVELOPMENT OF 
INFECTION IN SEVERELY INJURED PATIENTS  
 
6.1 Introduction 
Hemorrhage following traumatic injury is a leading cause of global mortality and 
morbidity (193).  Tranexamic acid (TXA) has demonstrated survival benefits in trauma 
patients in a single large multicentre randomized control trial (64) and a subsequent 
military study (203).  This has led many services to include TXA in their major 
hemorrhage protocols (196, 204).  Mortality benefits following early TXA use appear 
greatest in those patients who are the most shocked, requiring massive transfusion 
(191, 203).  There is an on-going debate however as to whether TXA may be of benefit 
to all trauma patients, based on a prespecified analysis of the CRASH-2 results (239). 
Furthermore, while TXA may improve survival it may also be beneficial for other 
outcomes such as infection, given its known mechanisms of action (240).  The 
interconnection between haemorrhage and inflammation is well described (187, 241), 
and TXA has anti-inflammatory properties (242). TXA blocks the plasminogen and 
plasmin receptor binding sites resulting in a decreased inflammatory response (206). 
Evidence from cardiac surgery suggests that pre-operative TXA may also attenuate 
inflammation through inhibition of fibrinolysis (243, 244).  
 
The effects of TXA on infection and other non-mortality outcomes such as organ failure 
have not been described.  In chapter three I described the relationship between 
admission shock and infection. In chapter five the presence of fibrinolysis at 24 hours 
post injury was found to be strongly associated with the development of infection. 
Consequently, the utility of TXA in the timely management of haemorrhage and 
coagulopathy may reduce the incidence of infection.  
 
110 
 
6.2 Study objective and aims 
The overall objective of this study was to characterise the relationship between TXA use 
and clinical outcomes in a severely injured civilian cohort.  
The primary aim was to assess the effect of TXA on the development of infection, and to 
determine any differential effect between patients who presented to hospital with and 
without shock.   
Secondly, to evaluate the effect of TXA on multiple organ failure, mortality and other 
clinical outcomes.  
 
 
6.3 Methods  
6.3.1 Patient selection 
All adult trauma patients (>15 years), admitted to the critical care unit following trauma 
team activation over a two year period were recruited. In order to focus on a severely 
injured cohort, all patients admitted to critical care were initially included and then 
those whose ISS was calculated to be <16 were retrospectively excluded. Overall injury 
severity was classified using the Injury Severity Score (ISS) (29).   
 
The Emergency Department (ED) has a ‘Code Red’ major hemorrhage protocol (MHP) to 
guide blood product replacement during trauma resuscitation.  At the start of the study 
period, TXA 1g was administered in the ED within three hours of injury, followed by a 1g 
infusion at the discretion of the trauma team leader when hemorrhage was detected or 
suspected. Three months into the study, TXA was formally introduced into the MHP, 
following the standard CRASH 2 protocol (64). Patients are given 1g in the first three 
hours following injury followed by a 1g infusion over eight hours. This initial dose is 
administered either by clinicians in pre hospital care (PHC) or the ED if the systolic blood 
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pressure (SBP) is <90mmHg, there is a poor response to an initial fluid bolus and there is 
suspected active hemorrhage.  
 
6.3.2  Data collection  
Data were collected prospectively on patient demographics, mechanism of injury (blunt 
or penetrating force), baseline physiology and clotting profiles.  Arterial blood analysis 
for base deficit (BD) measurement was performed during the trauma team resuscitation 
on admission as part of normal processes of care. The presence of clinically significant 
shock known to be strongly associated adverse outcome was defined as a BD ≥6mEq/L 
(208). Time to operation or interventional radiology from admission was recorded. 
Crystalloid, PRBC, FFP, Platelets and Cryoprecipitate use in the first 24 hours following 
admission were documented.  
 
6.3.3 Outcome measures 
The primary outcome was infection, defined using the Centre for Disease Control and 
Prevention (CDC) criteria as a ‘localised or systematic condition resulting from an 
adverse reaction to the presence of an infectious agent(s) or its toxin(s) occurring ≥48 
hours post admission’ (209). Further information on the methods used for the 
identification of infection is described in chapter 2.4.1.  
 
The secondary outcomes evaluated were in hospital mortality at ≤48 hours (early) and 
>48 hours (late) post injury, the presence of multiple organ failure, episodes of venous 
thromboembolism (VTE), stroke and myocardial infarction, ventilator free days (VFD), 
critical care length of stay (LOS) and total hospital LOS. The development of organ 
failure was assessed daily using the Sequential Organ Failure Assessment (SOFA) score. 
Single organ failure (SOF) was defined as a SOFA score of ≥3 in one organ system during 
a 24 hour period. Multiple organ failure (MOF) was defined as SOF in two or more organ 
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systems during a 24 hour period (176).  Organ failure scoring systems are described in 
more detail in chapter 2.4.2.   
 
VTE, stroke or myocardial infarction were diagnosed by the clinical team independent of 
the researcher. The presence of VTE was confirmed by either ultrasound scan (for deep 
vein thrombosis) and/or computed tomography pulmonary angiography (CTPA) (for 
pulmonary embolism).  Stroke was confirmed using CT scan and the diagnosis of 
myocardial infarction was made utilising ECG, echocardiogram and troponin T and I 
tests.   Patients were followed until hospital discharge, transfer or death.   
 
6.3.4 Data analysis 
Statistical analysis was performed using GraphPad PRISM v5 (GraphPad Software Inc, 
San Diego CA USA) and SPSS v21 (IBM Corporation, Armonk, NY, USA). Mann Whitney U 
test or Kruskal Wallis test were used to analyse non-parametric data and expressed as 
median (interquartile range). Parametric data was analysed with Students t-test or 
ANOVA, and expressed as mean (95% confidence intervals).  Percentages were analysed 
using Chi square or Fisher’s exact tests.   
 
Multivariable linear and binary logistic regression models were created to identify if TXA 
was independently associated with infection and other outcomes.  Initially, univariate 
statistical analysis was performed to examine the unadjusted effects of potential 
predictor variables.  There were a large number of variables to be entered into the 
models. Following statistical advice those variables achieving a significance of p<0.2 
were added to the multivariate regression models for stepwise regression analysis.   
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6.4 Results 
In the two-year period, 456 patients were admitted to critical care following traumatic 
injury and were initially included in the study. Of these, 71 patients had an ISS <16 and 
were subsequently excluded, leaving 385 patients in the study.   160 patients (42%) 
received TXA as part of the major hemorrhage protocol within three hours following 
injury in either PHC or ED (Table 6.1).  
 
Table 6.1 Admission demographics, injury characteristics and transfusion 
requirements: all patients 
 All  
no TXA (n=225) 
All  
TXA (n=160) 
PHC scene to ED arrival (mins)^ 56 (54-59) 54 (51-57) 
Ageˆ 40 (38-43) 42 (39-44) 
Male (%) 82 78 
Blunt (%) 93 84 
ISSˆ 29 (27-30) 33 (31-35)* 
AIS≥3 head (%) 64 65 
GCSˆ 10 (10-11) 10 (9-10) 
SBPˆ(mmHg) 127 (123-131) 102 (97-107)* 
BDˆ (mEq/L) 3 (2.7-4) 7.7 (5.8-7.5)** 
INRˆ 1.1 (1.1-1.1) 1.3 (1.2-1.3)** 
Time to OR/IR (mins)~ 120 (47-306) 54 (30-120)** 
   
Transfusion in first 24H from 
injury: 
  
PRBC (units)ˆ  2 (1-3) 7 (6-8)** 
FFP (units)ˆ 1 (1-2) 5 (4-6)** 
PLTS (units)ˆ 0 (0-0) 1 (0-1)* 
CRYO (units)ˆ 0 (0-0) 1 (1-2)* 
Crystalloid (mls)ˆ 643 (474-812) 942 (752-1133)* 
   
Values are expressed as ˆmean (95% Confidence Intervals),  ~median (IQR) or %.  No shock = BD<6 mEq/L,  Shock = 
BD≥6 mEq/L, PHC: Pre hospital care, ED: Emergency department, ISS: Injury severity score, AIS: Abbreviated injury 
score, GCS: Glasgow Coma Score, SBP: Systolic blood pressure, BD: Base deficit, PRBC: Packed red blood cells, FFP: 
Fresh frozen plasma, PLTS: Platelets, CRYO: Cryoprecipitate, OR: Operating Room, IR: Interventional Radiology. * 
indicates p <0.05 and ** p<0.01 when comparing two groups.  
 
 
6.4.1 The effect of TXA in all patients 
Overall, patients who had TXA were older, suffered more penetrating trauma and were 
found to have a significantly higher ISS than those in the no-TXA group (Table 6.1). 
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Patients who received TXA were more shocked (p<0.01) and more coagulopathic 
(p<0.01) on admission to hospital. Time to haemorrhage control for patients receiving 
TXA was half that of those in the no-TXA cohort (p<0.01). There was a three-fold 
increase in PRBC transfusion and a five-fold increase in FFP administration for patients 
in the TXA group (Table 6.1).  For all patients infection rates were high, with no 
significant differences between the two groups (No TXA: Infection - 50% vs. TXA: 
Infection - 56% ns) (Table 6.2). Unadjusted mortality rates between the two groups 
were the same. The incidence of MOF was lower for those who received TXA compared 
to those who did not, however this did not achieve significance (No TXA: 37% vs. TXA: 
30% ns).  
 
Table 6.2 Clinical outcomes: all patients 
 All no TXA (n=225) All TXA (n=160)  
Infection (%) 113 (50) 89 (56)  
Mortality≤48H (%) 19 (8) 12 (8)  
Mortality>48H (%) 18 (8) 17 (11)  
    
Respiratory failure (%)  56 (26) 42 (27)  
CVS failure (%) 103(47) 81(52)  
CNS failure (%) 87(40) 43(27)  
Coagulation failure (%)  5(2) 5(3)  
Hepatic failure (%) 2(1) 5(3)  
Renal failure (%)  9(4) 9(6)  
MOF (%) 82(37) 46(30)  
    
VTE (%) 9(4) 8(5)  
Stroke (%) 3 (1) 5 (3)  
M. Infarction (%) 3 (1) 3 (2)  
    
28/7 VFD
†
 23 (18-27) 22 (14-26)*  
CC LOS
†
 7 (3-12) 10 (4-18)*  
Hospital LOS
†
 27 (14-40) 30 (16-49)*  
Values are expressed as 
†
median (IQR) or n (%).  No shock = BD<6 mEq/L, Shock = BD≥6 mEq/L,   MOF: Multi-organ 
failure, VTE: Venous thromboembolism, M. Infarction: Myocardial infarction, 28/7 VFD: 28 day ventilator free days, 
CC LOS: Critical care length of stay.   * indicates p <0.05 when comparing two groups 
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6.4.2 The effect of TXA and shock 
One hundred and twenty eight patients were in shock (BD ≥6 mEq/L) on arrival to the 
ED and of these, 84 (65%) patients were given TXA (Table 6.3). Those in the TXA group 
were more hypotensive on arrival to hospital (p=0.01) and more severely injured. 
Administration of PRBC and FFP transfusions was almost 50% higher for patients who 
received TXA compared to those who did not (Table 6.3).  
 
Table 6.3 Admission demographics, injury characteristics and transfusion 
requirements:  shocked and non-shocked patients 
 Shock 
no TXA (n=47) 
Shock 
TXA (n=84) 
No shock 
no TXA (n=178) 
No shock TXA 
(n=76) 
PHC scene to ED arrivalˆ 
(mins) 
55 (51-60) 55 (49-60) 56 (53-59) 53 (49-58) 
Ageˆ 38 (33-43) 39 (36-43) 43 (18.9) 41 (18.6) 
Male (%) 80 81 86 80 
Blunt (%) 90 84 88 85 
ISSˆ 31 (29-35) 35 (32-38) 27 (26-29) 31 (27-33)* 
AIS≥3 head (%) 55  52 67 46* 
GCSˆ 9 (8-10) 9 (8-11) 10 (9-11) 12 (11-13)* 
SBPˆ(mmHg) 109 (100-118) 94 (87-102)* 132 (127-135) 110 (103-118)* 
BDˆ (mEq/L)(mEq/L) 10 (9-12) 12 (11-13) 1.4 (1.1-1.9) 2 (1.3-2.6) 
INRˆ 1.2 (1.1-1.3) 1.3 (1.1-1.4) 1.1 (1.0-1.1) 1.1 (1.1-1.2)* 
Time to OR/IR (mins)~ 62 (32-454) 48 (30-113) 120 (55-300) 64 (33-133)* 
Transfusion in first 24H:     
PRBC (units)ˆ  6 (3-8) 10 (8-12)* 1 (0-1) 5 (4-6)* 
FFP (units)ˆ 4 (2-6) 7 (5-8)* 1 (0-1) 4 (3-5)* 
PLTS (units)ˆ 1 (0-1) 1 (1-2)* 0 (0-0) 1 (0-1)* 
CRYO (units)ˆ 1 (0-1) 2 (1-2)* 0 (0-0) 1 (0-1)* 
Crystalloid (mls)ˆ 730 (165-1315) 710 (457-967) 610 (418-705) 900 (636-1258) 
Values are expressed as ˆmean (95% Confidence Intervals), ~median (IQR) or %.  Shock = BD≥6 mEq/L,           No shock 
= BD<6 mEq/L, PHC: Pre hospital care, ED: Emergency department, ISS: Injury severity score, AIS: Abbreviated injury 
score, GCS: Glasgow Coma Score, SBP: Systolic blood pressure, BD: Base deficit, PRBC: Packed red blood cells, FFP: 
Fresh frozen plasma, PLTS: Platelets, CRYO: Cryoprecipitate, OR: Operating Room, IR: Interventional Radiology. * 
indicates p <0.05 when comparing two groups 
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Incidence of infection was high but there were no significant differences between the 
groups (No TXA: 62% vs. TXA: 54%, ns) (Table 6.4). Early unadjusted mortality rates for 
those who had TXA were lower (Table 6.4). There was significantly less respiratory 
failure following TXA administration, and rates of MOF were significantly lower for 
those who had TXA (No TXA: 46% vs. TXA: 29%, p=0.02). There was however a four-fold 
increase in thromboembolic events in the TXA group (No TXA: 2% vs. TXA: 8%, p<0.01).  
 
Table 6.4  Clinical outcomes: shocked and non-shocked patients 
 Shock 
no TXA (n=47) 
Shock 
TXA (n=84) 
No shock 
no TXA (n=178) 
No shock 
TXA (n=76) 
Infection (%) 29(62) 45(54) 85(48) 43(57) 
Mortality≤48H (%) 8 (15) 9 (11) 10 (6) 4 (5) 
Mortality>48H (%) 4 (9) 9 (11) 15 (9) 7 (9) 
     
Respiratory failure (%)  19(39) 20(24)* 37(22) 22(29) 
CVS failure (%) 28(57) 51(65) 75(45) 30(40) 
CNS failure (%) 15(31) 20(25) 72(43) 23(30) 
Coagulation failure (%)  3(6) 4(5) 2(1) 1(1) 
Hepatic failure (%) 2(4) 5(6) 0(0) 0(0) 
Renal failure (%)  4(8) 7(9) 5(3) 2(3) 
MOF (%) 22(46) 24(29)* 60(36) 22(29) 
     
VTE (%) 2(2) 7(8)* 7(4) 1(1) 
Stroke (%) 2 (4) 4 (5) 1 (1) 1 (1) 
M. Infarction (%) 2 (4) 3 (4) 1(1) 0 
     
28/7 VFD
†
 17 (5-23) 20 (16-26)* 24 (18-27) 25 (17-26) 
CC LOS
†
 11 (4-18) 12 (7-20) 7 (3-10) 7 (3-13) 
Hospital LOS
†
 30 (16-50) 30 (10-45) 18 (9-31) 26 (14-47) 
Values are expressed as 
†
median (IQR) or n (%).  No shock = BD<6 mEq/L, Shock = BD≥6 mEq/L, MOF: Multi-organ 
failure, VTE: Venous thromboembolism, M Infarction: Myocardial infarction, 28/7 VFD: 28 day ventilator free days, CC 
LOS: Critical care length of stay. * indicates p <0.05 when comparing two groups 
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Of the 254 patients who were not shocked on arrival, 76 (30%) were given TXA (Table 
6.3). Furthermore there was a 50% decrease in time to haemorrhage control for those 
who received TXA in this cohort (No TXA: 120 minutes vs. TXA: 64 minutes, p<0.01) and  
there was a five-fold increase in PRBC use and four times greater FFP transfusion 
administered to the TXA group (Table 6.3).  
 
There were no significant differences in the development of infection between the two 
groups in the non-shocked cohort (No TXA: Infection - 48% vs. TXA: Infection - 57% ns) 
(Table 6.4). Unadjusted early and late mortality rates between the two groups were 
similar. There was a trend to a decreased incidence of MOF in the TXA group however 
this did not reach significance. Finally, there was no significant increase in the 
development of thromboembolic events for non-shocked patients irrespective of TXA 
administration. 
 
Multivariate analysis was used to identify if TXA was independently associated with TXA 
and other clinical outcomes.   Univariate analysis of all admission variables (from Tables 
6.1 and 6.3) was performed to determine factors for multivariable analysis (Table 6.5). 
Logistic regression evaluated the effect of TXA on binary outcomes (infection, MOF, 
mortality, VTE, stroke and myocardial infarction). The effect of TXA on continuous 
outcomes (ventilator free days, critical care length of stay and hospital length of stay) 
was analysed using multivariable linear regression (Table 6.6). 
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Table 6.5 Clinical variables significantly associated with outcome in univariate 
analysis  
Dependent 
variable 
Independent 
variable 
All patients Shock cohort No shock cohort 
Infection ISS 0.08 Ns Ns 
 BD <0.01 0.02 0.01 
 PRBC 0.04 Ns 0.04 
 TXA 0.07 0.14 0.90* 
 GCS Ns 0.08 0.01 
 INR Ns 0.18 Ns 
     
Mortality Age <0.001 Ns <0.01 
 GCS <0.001 0.05 0.10 
 Blunt mechanism 0.01 Ns Ns 
 TXA 0.08 0.02 0.19 
 PRBC <0.01 0.03 <0.01 
 BD <0.001 0.16 Ns 
 INR Ns Ns 0.07 
 ISS Ns Ns 0.17 
 TTOR/IR Ns 0.09 Ns 
     
MOF ISS <0.01 <0.01 0.04 
 BD <0.001 Ns Ns 
 TXA 0.06 <0.01 0.19 
 PRBC 0.01 0.04 Ns 
 GCS Ns Ns <0.01 
 TTOR/IR Ns 0.01 Ns 
     
VTE TXA 0.42* 0.16 0.32* 
 Gender 0.20 0.05 Ns 
 Blunt mechanism Ns 0.08 Ns 
     
Stroke/MI TXA 0.24* 0.21* 0.83* 
 ISS Ns Ns 0.16 
 BD Ns 0.19 Ns 
 Gender 0.20 Ns Ns 
GCS: Glasgow coma score, TXA: Tranexamic Acid, PRBC: Packed red blood cells, BD: Base Deficit, INR: 
International normalised ratio, ISS: Injury severity score, TTOR/IR: Time to operating room or 
interventional radiology, MOF: Multi-organ failure, VTE: Venous thromboembolism, MI: Myocardial 
infarction. *Following statistical advice, multivariate analysis of TXA on all outcomes was included in the 
table whether p<.20 or not, ns: not significant. 
 
Multivariable logistic regression revealed that TXA was not independently associated 
with a reduction in infection for any of the cohorts within this study (Figure 6.1).  
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Figure 6.1. The effect of TXA on binary outcomes in all, shock and no-shock cohorts. Forest plot shows 
odds ratio and 95% confidence intervals for the effect of TXA on each binary outcome. MOF: Multiple 
organ failure, VTE: Venous thromboembolism, MI: Myocardial infarction. †p=0.03, * p=0.01. 
 
There was a trend to a protective relationship between TXA and infection in the 
shocked cohort. Although this didn’t achieve significance in regression analysis, the 
odds ratio of 0.7 suggested a beneficial association which may have become significant 
with a larger cohort. TXA was independently associated with a reduction in MOF and 
mortality in shocked patients (Figure 6.1). Furthermore, shocked patients also had a 
greater number of ventilator free days after TXA use (Table 6.6).  However, TXA was not 
independently associated with any change in infection, mortality, MOF or other 
outcomes in the non-shocked cohort, (Figure 6.1).  
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Table 6.6 Multivariate linear regression: the effect of TXA on continuous 
outcomes 
 β-coefficient 95% CI p value R square 
All cohort     
VFD  -.079 -2.5 - .08 0.06 0.38 
CCLOS  .081 -.35 – 4.7 0.09 0.24 
HLOS  0.19 -4.4 – 6.7 0.69 0.19 
Shocked cohort     
VFD  3.80 4.1 – 7.2 0.02 0.51 
CCLOS  4.67 -1.1 - 10.4 0.11 0.21 
HLOS  -3.88 -17.2 – 9.4 0.56 0.17 
No shocked 
cohort 
    
VFD  -.844 -2.8 – 1.2 0.41 0.30 
CCLOS  1.35 -2.0 – 4.7 0.43 0.14 
HLOS  .111 -.47 – 14.2 0.07 0.14 
Shock = BD≥6 mEq/L, no shock = BD<6 mEq/L, VFD: ventilator free days, CCLOS: critical care length of stay,               
HLOS: hospital length of stay.  
 
 
6.5 Discussion  
This prospective study has characterised the relationship between TXA use in severely 
injured civilian patients and infection. TXA administration did not have an independent 
relationship with the development of infection in any of the study cohorts. TXA use was 
associated with improved mortality and organ failure in patients presenting with shock. 
Yet there were no clear outcome benefits identified for patients who arrived to hospital 
without shock.  However there was no independent association between TXA use and 
adverse events in this study. 
 
Overall infection rates were high for all cohorts within the study. TXA is known to inhibit 
the activity of the plasminogen-plasmin pathway (206) resulting in a reduction of both 
inflammation and fibrinolysis (186, 191, 244). Whilst an independent relationship was 
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not observed in this relatively small sample of participants, there was a trend to 
reduced infection following TXA only in shocked patients, where the mechanism of 
action may have greatest utility.  
 
TXA administration was associated with reduced rates of organ failure, which is known 
to be associated with poor outcomes (23).  The significantly lower rates of respiratory 
failure in shocked patients who received TXA were consistent with the increased 
number of ventilator free days. Although the incidence of MOF in the overall cohort was 
high, patients were more severely injured than in the previous TXA studies (64, 203).  
Following TXA administration there was a reduction in MOF in shocked patients. This 
was despite the presence of admission coagulopathy and increased rates of blood 
transfusion, both of which are reportedly associated with the development of MOF (68, 
69, 175). Trauma related plasmin generation in bleeding patients is known to produce 
proinflammatory responses which may be responsible for the development of MOF 
(240). The anti-inflammatory effects of TXA may be responsible for the observed 
reduction in single and multiple organ failure associated with shock and hemorrhage.   
 
TXA use was also associated with decreased early mortality and was protective for 
adjusted all-cause mortality in shocked patients. The non-significant increase in late 
crude mortality may be the result of improved early survival in a more severely injured, 
shocked cohort of patients who presented with lower systolic blood pressures and had 
greater transfusion requirements. Overall the beneficial effect of TXA on mortality in 
shocked trauma patients reported previously was also evident early in this civilian 
trauma population (64). After adjusting for confounding variables in the non-shocked 
cohort, there was no effect of TXA on infection and mortality, and only a non-significant 
trend towards reduction in MOF. 
 
Although VTE was more common in patients who received TXA, this again may be due 
to its administration to a more severely shocked population with longer initial survival 
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rates.  There may also have been a delay in instituting thomboprophylaxis in a more 
severely injured patient group. However there was no statistically significant 
relationship in the multivariate analysis which if anything showed a trend to a reduced 
risk of VTE after TXA in shocked patients.  This is consistent with the reduced 
thrombotic event rates observed in the CRASH 2 study (64).   
 
In this study BD was used as a marker of tissue hypoperfusion, rather than systolic 
blood pressure which is utilised in the major haemorrhage protocol. Systemic tissue 
hypoperfusion is known to drive fibrinolysis in trauma (183). Whilst BD is available as a 
point of care test in many EDs, it is unlikely to be used in PHC and waiting for BD results 
could potentially delay administration of TXA. However, clinical markers such as blood 
pressure are known to be poor indicators of the degree of systemic hypoperfusion (207, 
208). In the CRASH 2 subgroup analysis, the most pronounced benefits of TXA were 
seen in patients with SBP<75mmHg (64). This threshold would potentially miss a large 
number of patients with significant hypoperfusion. Further work is needed to identify 
parameters for use in clinical practice associated with clinically important fibrinolysis in 
trauma. 
 
There are a number of limitations to this study. Primarily it was conducted in a single 
setting, albeit a large urban major trauma centre. The numbers within the sub cohorts 
were relatively small and the non-significant infection results may have become 
significant with a larger number of participants, especially for those in the shocked 
group. This represents an avenue for further study, especially when considering the 
relationships found in previous chapters between shock, coagulation changes and 
infection. Finally, data was not collected on the use of or adherence to 
thomboprophylaxis guidelines during the study, which may have assisted with the 
analysis of VTE. Despite the limitations, the findings give a clear signal for using TXA in 
severely injured, shocked civilian patients in order to benefit clinical outcomes. 
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6.6 Conclusion 
In conclusion, this is the first study to show that the use of TXA as part of a major 
hemorrhage protocol provides outcome benefits specifically for severely injured 
shocked patients. In particular, TXA was independently associated with a reduction in 
MOF and mortality in patients presenting to hospital in a hypoperfused state.  An 
independent relationship between TXA and infection was not observed, however these 
results will serve as a basis for future work.  This includes prospective studies to better 
understand the relationship and mechanistic pathways between inflammation, infection 
and TXA use in a larger cohort of shocked patients. 
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CHAPTER SEVEN CONCLUSIONS, STRENGTHS AND LIMITATIONS OF THE 
RESEARCH 
 
7.1 Summary of thesis and suggestions for future work 
The research I have described in this thesis has achieved the aims proposed in chapter 
one. The findings have provided novel contributions to the existing evidence on 
predictors of infection after trauma.  Chapter three described the burden of infection 
for severely injured civilian patients and demonstrated its association with admission 
hypoperfusion which has not been previously reported. In chapter four the relationship 
between changes in immune cell responses and infection was confirmed.   Lymphopenia 
prolonged to day four post injury was strongly predictive of the development of 
infectious complications.  Persistent lymphopenia still present at four days post injury 
has previously been linked with increased mortality (162). I was able to add to this 
evidence by confirming that lymphopenia at day five is also associated with mortality 
after severe injury. Chapter five demonstrated that coagulopathy, specifically activation 
of anticoagulant and fibrinolytic pathways, which was not corrected by 24 hours post 
injury was associated with infection. Furthermore the degree of coagulation dysfunction 
directly correlated with the incidence of infection. Lastly, chapter six was the first study 
to evaluate early antifibrinolytic therapy and its effect on infection and other clinical 
outcomes in a severely injured cohort. There was no significant beneficial relationship 
between TXA and the development of infection. However it was associated with 
improved MOF and mortality for patients presenting to hospital in a hypoperfused 
state, and thus adds to the current understanding of the utility of TXA in trauma.  
 
 
This research has allowed me to demonstrate that infection is a significant cause of 
morbidity following severe injury, and the burden for this population was greater than 
previously appreciated. Hospital associated infections are of concern for all healthcare 
providers and many infection prevention and control guidelines are advocated (121, 
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213, 245). However in this research, drivers or predictors of infection were found to be 
related to the patients presentation in the initial period after severe injury. The 
predominant early characteristic predictive of infection was admission hypoperfusion. 
Once admitted to hospital, patients had significant alterations to their coagulation and 
immune systems in the first few hours and days from injury which were subsequently 
associated with the development of infection.  
 
My findings suggest that there is the potential for an early clinical window where 
modulation of the coagulation and immune system changes could provide an 
opportunity to reduce the burden of infection. Antifibrinolytic therapy is already utilised 
in clinical trauma haemorrhage management (193) and may play a beneficial role in 
reducing infection in a larger patient population. Further investigation into optimal 
resuscitation and transfusion practice which may help to modify coagulation-
inflammation pathways is warranted.   
 
In the studies described within this thesis, patients who developed infection in critical 
care had longer lengths of stay. This prolonged their post injury recovery and may have 
had negative effects on the patient experience in hospital. Infection may also have a 
detrimental impact on post-discharge recovery or readmission rates. Infectious 
complications after severe injury also worsens economic burden. The increased costs 
associated with treating infections and prolonged length of stay following trauma are 
reported to be double that of non-infected patients (73, 136). Future work should focus 
on timely haemorrhage control and correction of coagulopathy which may result in 
reduced infections after trauma, improve patient recovery and decrease economic 
burden.  
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7.2 Strengths and limitations of the research 
This thesis reports the findings from four prospective studies, conducted at a large 
urban major trauma centre. To best evaluate those most at risk of infection, severely 
injured critical care patients were chosen as the study population. Data was collected 
contemporaneously on a daily basis. This resulted in complete, quality data capture 
which measured a number of complex interventions and outcomes.  The studies used 
data definitions that were consistent with internally agreed standards (such as those for 
infection or organ failure), helping to minimise variance and increase the 
generalizability of findings. 
 
Robust multivariate models were used to establish strong relationships between a 
number of significant trauma variables and infection. The presence of admission shock, 
fibrinolysis at 24 hours post injury and lymphopenia to day four after admission were all 
strongly associated with the development of infection.  Therefore, the findings have 
provided potential clinical indicators for trauma clinicians to identify those patients at 
risk of infection following severe injury. Finally, there was a high incidence of infection 
in severely injured patients in all of the studies. This significant finding suggests that 
infection has the potential to be used as sensitive measure of outcome in other trauma 
research studies and clinical trials.  
 
I have acknowledged a number of limitations within this thesis. Whilst multivariate 
analysis reduced the effect of confounding variables, many of the predictions of 
infection were based on associations in relatively small study populations. Findings 
implicating haemorrhage, coagulation and antifibrinolytics in the development of 
infection would benefit from substantiation in future studies with larger numbers and 
greater statistical power. Other than the use of TXA and blood products, the role of 
acute phase care was not investigated therefore further research examining early 
intervention for trauma patients known to be or suspected of bleeding and the effect 
on infection is warranted.  
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 There was a strong association between unresolved lymphopenia and infection, 
however the mechanistic link between the two was not investigated and requires 
further immunological characterisation. Furthermore, sampling immune cell counts for 
a longer time period may have yielded further results in patients who developed 
infection later in their clinical course associated with prolonged or persistent organ 
failure (PICS).  
 
Bacterial pathogens are increasingly resistant to broad spectrum antibiotics and the 
development of new antibiotics is limited (131, 246, 247). Adherence to antibiotic 
stewardship is a key focus for military trauma research (134, 248). In my studies, the 
majority of trauma patients were given prophylactic antibiotics. No differences were 
found in the development of infection between those who received prophylaxis from 
admission and those who did not. However further investigation of the utility and 
adherence to prophylactic antibiotic guidance may add to the characterisation of 
trauma infections, and further work with civilian patients is warranted.  
 
Finally, I did not compare outcomes following discharge from hospital between patients 
who did and did not develop infection. The effects of infection developed in critical care 
following injury may be far reaching. Understanding longer term physical and 
psychological consequences of infection may provide important patient and system 
performance outcome measures. 
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7.3 Conclusion 
This thesis has completed all of the study aims and has characterised important 
predictors of infection following trauma.  Infection continues to be a significant burden 
for severely injured patients, resulting in adverse outcomes whilst in hospital. Admission 
shock, altered coagulation at 24 hours and prolonged lymphopenia following injury 
were found to be independent predictors of infection.  Early use of antifibrinolytics had 
no significant impact on infection rates, however was associated with reduced mortality 
and organ failure. Further research into the effects of early coagulation and immune cell 
modulation on the development of infection is needed.  
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